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Abstract
Class LA. phosphoinositide 3-kinases (PI(3)Ks) are critical control elements of 
signalling cascades with influence over cell survival, proliferation and migration. 
Mammals have 3 distinct class IA PI(3)K catalytic subunits. One of these, p i 105, is 
preferentially expressed in leukocytes.
Previous murine genetic studies using strategies which target regulatory elements 
thereby disrupting class LA PI(3)K signalling indiscriminately of the catalytic 
subunits have established that PI(3)K are important for Kit signalling and mast cell 
homeostasis but not for mast cell activation and the allergic response.
We have utilised a mouse model in which p i 105 is inactivated by introduction of a 
germline mutation in the ATP binding site, creating p i 105D910A , mimicking the 
effects of a pharmacological inhibitor for p i 105.
Bone marrow mast cells (BMMCs) from p i 1 o5D910A/D910A mice have severe defects 
in SCF/Kit responses including proliferation, migration and adhesion; additionally 
BMMCs derived from these mice have a substantial defect in antigen receptor 
signalling and mast cell degranulation, pi 105D910A mice have tissue site-selective 
loss of mast cell populations and a substantial reduction in IgE/Ag-induced passive 
cutaneous anaphylaxis response. Using pi 105 iso form-selective inhibitors it is 
possible to replicate our genetic strategy and completely block the in vivo allergic 
immune response. Furthermore using such compounds and human mast cells we 
show that our findings have direct relevance to the human system.
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Our data identify p i 106 as critical to homeostatic (through its role in growth factor 
dependent responses) and pathologic phases of mast cell biology (through its role in 
driving FcsRI-dependent responses) and point towards a promising future for using 
p i 106 inhibitors to treat mast cell-associated pathological disorders.
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Chapter 1  Introduction
1. Introduction
1.1 The Mast cell and Phosphoinositide 3-kinase
The immune system is a large, complex network of cells, receptors and chemical 
mediators which maintains the homeostasis of an organism. Scientific discoveries 
over the last century have helped identify the various components of the immune 
system and describe how these cells and their mediators protect us against disease.
The protective role of the immune system is tightly regulated and is designed to be 
self-limiting once the pathologic condition has been resolved, however in the rare 
instances when this regulation breaks down or in people with genetic predispositions 
the immune system can promote diseases such as allergy, autoimmunity and even 
cancer.
The immune system is divided into two broad sections, namely the innate (non­
specific) and adaptive (specific). The innate immune response is the frontline against 
bacterial and viral infections, rapidly responding to foreign material by phagocytosis 
and by releasing reactive chemical species which non-specifically destroy material 
within the site of inflammation. In contrast, the adaptive immune response is slower 
to respond, relying on antigen presenting cells of the innate immune system 
including macrophages and dendritic cells to help capture and present foreign 
material which it utilises to mount a highly specific cellular and humoral, T and B 
cell dependent secondary response upon subsequent exposure.
20
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More recently it has been realised that some cells within the immune system 
including the mast cell can cross these boundaries between innate and adaptive 
immunity with roles in both sections of the immune system.
The mast cell is a tissue-resident effector cell of bone-marrow origin that responds to 
both endogenous and exogenous stimuli with immediate and delayed release of 
inflammatory mediators. Mast cells have long been implicated in the pathology and 
mortality of anaphylaxis and other allergic disorders by virtue of their ability to be 
activated through antigen that binds antigen-specific immunoglobulin-E (IgE) bound 
to the mast cell surface (Metcalfe, Baram et al. 1997; Wedemeyer and Galli 2000). 
More recently the mast cell has been linked to pathologies beyond IgE and allergic 
disease. The developing paradigm for mast cell function integrates critical roles in 
innate and adaptive immunity together with accessory functions in diverse 
pathological conditions including autoimmunity and cancer (Lee, Friend et al. 2002; 
Galli, Kalesnikoff et al. 2005; Littlepage, Egeblad et al. 2005; Nigrovic and Lee 
2005; Wedemeyer and Galli 2005).
Phosphoinositide 3-kinases (PI(3)Ks) are a group of enzymes that produce 
intracellular second messenger lipids and initiate intricate signaling cascades with 
influence over cell homeostasis and activation (Carpenter and Cantley 1996;
Fruman, Meyers et al. 1998; Vanhaesebroeck, Leevers et al. 2001; Vanhaesebroeck, 
Ali et al. 2005). Recently described gene-targeted mouse models of PI(3)K subunits 
have highlighted the importance of this group of signal transducers in the immune
21
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system (Okkenhaug and Vanhaesebroeck 2003; Okkenhaug and Vanhaesebroeck 
2003; Deane and Fruman 2004; Fruman 2004; Vanhaesebroeck, Ali et al. 2005).
The focus of this work has been to further characterise PI(3)K signaling within mast 
cells and the allergic cascade. An in depth introduction and historical perspectives 
on mast cells and PI(3)K are beyond the scope of this section for which the reader is 
referred to several recent reviews (Carpenter and Cantley 1996; Metcalfe, Baram et 
al. 1997; Fruman, Meyers et al. 1998; Wedemeyer and Galli 2000; Vanhaesebroeck, 
Leevers et al. 2001; Puxeddu, Piliponsky et al. 2003 {Wymann, 2003 #12; Deane and 
Fruman 2004; Fruman 2004; Galli, Kalesnikoff et al. 2005; Vanhaesebroeck, Ali et 
al. 2005).
1.2 Mast cell biology
1.2,1 Origin and development
The mast cell is a 10-20 pm in diameter tissue-resident leukocyte with an in situ 
appearance ranging from ovoid to elongated (Schulman, Kagey-Sobotka et al. 1983; 
Metcalfe, Baram et al. 1997). Defined by the presence of dense cytoplasmic granules 
which cause the metachromasia when stained with toluidine blue, mast cells are 
haematopoietic in origin and differentiate from CD34+ bone marrow progenitor cells 
(Metcalfe, Baram et al. 1997; Puxeddu, Piliponsky et al. 2003).
Thy-110 Kithl FcsRI've progenitor cells migrate from the bone marrow into the 
circulation and under the influence of chemical messengers and cell adhesion
22
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molecules localise into vascularised mucosal and connective tissues, where they 
undergo final maturation (to become Fc£RI+ve) under the influence of stem cell 
factor (SCF) and the local environment (Metcalfe, Baram et al. 1997; Puxeddu, 
Piliponsky et al. 2003).
1.2.2 Survival and differentiation
The primary signal which maintains tissue mast cells is SCF which interacts with its 
receptor Kit (product of the Kit proto-oncogene) (Galli, Zsebo et al. 1994 {Metcalfe, 
1997 #55). Mice lacking functional membrane SCF (Sl/Sld) or with mutations within 
the Kit receptor (W/Wv) have a severe reduction in tissue mast cells (have less than 
< 1 % of wild-type mast cells in the skin and no detectable mast cells in the peritoneal 
cavity, respiratory tract, gastrointestinal tract, or other sites) (Metcalfe, Baram et al. 
1997; Galli, Kalesnikoff et al. 2005). Additionally T-cell derived cytokines such as 
interleukin (IL) -3, -4, -9 and -10, acting in synergy with SCF, can influence the 
development of mast cell subsets and the rapid proliferation of these cells under 
pathological conditions (Metcalfe, Baram et al. 1997; Puxeddu, Piliponsky et al. 
2003). In the presence of a normal SCF/Kit system, athymic nude mice lacking a T- 
lymphocyte system have site-selective loss of intra-epithelial mast cells and are 
unable to develop jejunal mast cell hyperplasia upon helminthic infection 
highlighting the vital importance o f T-cell cytokines for certain mast cell 
populations (Austen and Boyce 2001).
23
Chapter 1 Introduction
1.2.3 Heterogeneity
Mast cells develop in situ from circulating hematopoeitic CD34+ progenitor cells 
which are released from the bone marrow. Studies which have focused on the mouse 
intestine as a model system for mast cell development have shown that mast cell 
progenitors migrate from the circulation into the intestinal mucosa a process which 
is dependent upon the p7-integrin subunit.
Two main rodent mast cell subpopulations, the connective tissue mast cells (CTMC, 
also known as constitutive mast cells) and the mucosal mast cells (MMC, also 
known as the reactive mast cells) have been identified (Table 1) and characterised 
according to morphological and histochemical characteristics (Metcalfe, Baram et al. 
1997; Boyce 2003; Boyce 2004; Krishnaswamy, Ajitawi et al. 2006). The CTMC is 
particularly common in the skin and peritoneal cavity whereas the MMC is most 
common in the intestinal lamina propria. CTMC and MMC differ in size and 
histamine content and in function, including responsiveness to secretagogues and 
drug susceptibility (Metcalfe, Baram et al. 1997). MMC appear to be T-cell- 
dependent and can rapidly expand upon T-cell-dependent immune responses to 
certain intestinal parasites. In contrast, CTMC exhibit little or no T-cell dependence 
and are found in normal numbers in athymic nude mice (Metcalfe, Baram et al.
1997; Austen and Boyce 2001).
Human mast cells also exhibit heterogeneity with differences in size, histochemical 
properties, quantities of stored mediators, sensitivity to stimulation and drug 
susceptibility (Table 2) (Metcalfe, Baram et al. 1997). Like in rodents, human mast
24
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cells can be classified into two principle populations according to neutral protease 
content. Some human mast cells contain measurable levels of tryptase, chymase and 
carboxypeptidase, these cells are classified as M C tc  because they contain both 
tryptase and chymase (Metcalfe, Baram et al. 1997). In contrast the mast cells called 
MCj contain only tryptase (Metcalfe, Baram et al. 1997). The MCj type mast cell 
(corresponds most closely to MMC) is predominantly found in the alveolar septa of 
the lungs and in the small intestinal mucosa, whereas the M C tc  is mainly found in 
the skin and the intestinal sub-mucosa (and corresponds closely to the CTMC) 
(Metcalfe, Baram et al. 1997).
1.2.4 Activation
Polyvalent antigen cross-linking of immunoglobulin s (IgE) bound to FcsRI 
receptors triggers mast cell activation, this results in the release of pre-formed 
mediators, such as histamine and tryptase, but also in the synthesis and release o f 
newly generated lipid mediators, such as leukotriene (LT)B4, LTC4 and 
prostaglandin D2 and of a large number of cytokines, such as TNFa. Mast cell 
liberated pro-inflammatory mediators rapidly induce vasodilation and an increase in 
vascular permeability, brochial mucosa edema, mucus secretion and smooth-muscle 
contration, they also partcipate in eliciting an inflammatory-cell infiltrate (including 
neutrophils and eosinophils) which can further exacerbate the immediate 
hypersensitivity response. (Metcalfe, Baram et al. 1997; Wedemeyer and Galli 2000; 
Boyce 2003; Puxeddu, Piliponsky et al. 2003; Galli, Kalesnikoff et al. 2005). Mast 
cells may also be activated by a variety of non-immunological stimuli such as
25
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bacterial proteins and chemical agents including morphine sulphate, substance P, 
compound 48/80 and the anaphylatoxins C3a and C5a. Responsiveness to the 
activating stimuli appears to be dependent on the mast cell subset challenged, and 
the microenvironment (which itself can determine mast cell development) (Metcalfe, 
Baram et al. 1997).
The exact profile of mediators released is determined by the nature of the activating 
stimulus (Table 3) and is under the influence of the local environment in which 
activation takes place (Metcalfe, Baram et al. 1997; Wedemeyer and Galli 2000; 
Rivera, Cordero et al. 2002; Boyce 2003; Puxeddu, Piliponsky et al. 2003; Galli, 
Kalesnikoff et al. 2005).
26
Table 1.1 Mouse mast cells
Characteristics Peritoneal Cavity Mast cell Intestinal Mucosa Mast cell
Alternative names Connective tissue mast cell Mucosal mast cell
Size 10-20 pM 5-10 pM
Formaldehyde fixation Resistant Sensitive
Staining Safranin Alcian blue
T cell dependence in development No Yes
Protease content Chymase (Rat mast cell protease I) Chymase (Rat mast cell protease II)
Proteoglycan molecular mass Heparin 750-1000 kDa Chondroitin sulphate di B 100-150 kDa
Histamine 1 0 - 2 0  pg/cell 1 pg/cell
5-Hydroxy tryptamine 1 - 2  pg/cell <0.5 pg/cell
Prostaglandin D2 + +
Leukotriene C{ - ++
Activated by
FceRI aggregation Yes Yes
Compound 48/80 Yes No
Substance P Yes No
Inhibited by sodium cromoglycate Yes No
Table adapted from (Metcalfe, Baram et al. 1997)
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Table 1.2 Human mast cells
Characteristic m c t m c tc
Neutral protease Tryptase (10 pg/cell) Tryptase, Chymase, Carboxypeptidase,
Cathepsin G
Granule ultrastructure Scrolls Lattice/grating
T-cell dependence Yes No
Inhibited by sodium cromoglycate Yes No
Distribution %
Skin <1 >99
Alveolar tissue 93 7
Nasal mucosa 66 34
Tonsils 40 60
Small intestine
Mucosa 81 19
Submucosa 23 77
MCj , Mast cell with tryptase only, MCTC, Mast cell with tryptase and chymase. 
Table adapted from (Metcalfe, Baram et al. 1997)
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Table 1.3 Major m ast cell sec re ted  p roducts
Major mediators stored preformed 
in cytoplasmic granules
Histamine, serotonin (in murine mast cells), heparin, and/or chondroitin sulfates, neutral proteases 
(chymases and/or tryptases) major basic protein, many acid hydrolases, cathepsin, 
carboxypeptidases, peroxidase
Major lipid mediators produced on 
appropriate activation
PGE2, PGD2, LTB4 and LTC4, platelet-activating factor
Cytokines released upon 
appropriate activation
TNF, TGF-p, M IP-la, VPF/VEGF, FGF-2, LIF, IFN-a, IFN-p, IFN-y, GM-CSF, MCP-1, IL -la, 
IL-ip, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-9, IL-11, IL-12, IL-13, IL-15, IL-16, IL-18, IL-25 
(and probably many more)
Anti-microbial peptides Cathelicidin (called LL-37 in human mast cells, and cathelin-related antimicrobial peptide 
(CRAMP) in murine mast cells)
Table adapted from (Galli, Kalesnikoff et al. 2005)
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1.3 Mast cell function in pathology
1.3.1 Allergic disease
1.3.1.1 Thl and Th2 immune responses
The immune system is a disparate, far-flung collection of individual cells, cell 
aggregates, immune tissues and organs, thus the regulation of this complex ‘organ’ 
system is extremely challenging (Kidd 2003). This complex system is coordinated 
by T-helper (Th) cells which depending on the nature and the strength of the 
stimulus differentiate into either Thl or Th2 subsets and release a large variety of 
diffusible substances convey messages, give instructions and generally enable the 
whole system consisting of billions of immune cells to communicate with each other 
(Kidd 2003).
In the current literature Thl (cellular, infection fighting) cells and Th2 (humoral, 
allergy promoting) cells are invoked to rationalize virtually all known patterns of 
immune response. Thl cells are hypothesized to lead the attack against intracellular 
pathogens such as viruses, raise the delayed-type hypersensitivity skin response and 
fight cancer cells. Th2 cells are believed to emphasize protection against 
extracellular pathogens (such as parasites). It is also generally accepted that an 
overreactive Thl response can generate organ-speific autoimmune disease (e.g. 
arthritis, multiple sclerosis, type 1 diabeties) (Raz, Eldor et al. 2005). In contrast an 
imbalance towards a Th2 response is thought to be the underlying cause of allergy 
and systemic autoimmune disease (Kidd 2003; Agrawal and Bharadwaj 2005). 
However these stereotypes have proven to be oversimplistic, with the result that the
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Thl/Th2 hypothesis is increasingly criticized. Some reasons for these criticisms 
include the fact that human cytokine activities rarely fall into exclusive Thl or Th2 
patterns, non-regulatory T cells, or the antigen-presenting cells likely can also 
influence the immune response in a similar manner to Thl/Th2 cells.
Thl cells secrete a specific cytokine profile including interferon-y (IFN-y) and tumor 
necrosis factor (3 (TNFp) both of which are important in helping mount a cellular 
immune response. Thl T cell derived cytokines particularly IFN-y can antagonise 
the activity of Th2 cells. Interleukin-12 (IL-12), produced by macrophages plays an 
important role in inducing IFN-y production (Rogers, Zlotnik et al. 1991; Parronchi, 
De Carli et al. 1992). In contrast, Th2 cells secrete IL-4, IL-5, IL-9, IL-10 and IL-13, 
which are involved in isotype switching of B cells from immunoglobulin (Ig) M to 
IgE (IL-4 and IL-13) as well as proliferation and differentiation into antibody- 
secreting plasma cells (Romagnani, Annunziato et al. 2000). Interleukins-4 and IL- 
10 are also regulatory cytokines, antagonising the activities of Thl cytokines (Fig 
1.1) (Lester, Hofer et al. 1995).
Overall although the Thl/Th2 hypothesis has its limitations there is evidence for a 
Th2 cytokine pattern being important in allergic disease. This is evidenced by the 
success of allergen immunotherapy which has been shown to reduce the production 
of IL-4 in atopic individuals to levels observed in non-atopic individuals, the skew 
away from a Th2 pattern is followed by a shift towards a Thl profile (as concluded
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by increased IL-12 mRNA levels in patients receiveing this type of 
therapy)(Bousquet, Becker et al. 1991).
Th1 cell
A ntigen-presen ting  cell Host defence against
intracellular
organisms.Interleukin-12
CD4 cell
lnterleukin-4
lnterleukin-4
V J Allergic inflammation.
Induction of B cell 
Th2 Cell antibody production.
Fig 1.1 Th2 cells predominate in atopic disease. Differentiation o f Thl and Th2
depends on the cytokines interleukin-12 and interleukin-4, produced by antigen- 
stimulated precursor CD4 Tcells. Thl and Th2 cells are mutually antagonistic, in 
atopic individuals the Th2 T cells predominate and promote allergic disease.
1.3.1.2 A llergic cascade
Initial exposure to allergens leads to sensitization involving B cell isotype switching 
to IgE production and the formation of plasma cells which release IgE into the 
circulation (Romagnani, Annunziato et al. 2000). Circulating IgE binds to several
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cell types including basophils, eosinophils and the mast cell which has a pivotal role 
in allergic disease. Binding of IgE to its high affinity receptor expressed on the mast 
cell surface sensitizes the cell and functions as the mast cell antigen receptor. 
Subsequent exposure to the antigen leads to cross-linking of the mast cell IgE 
receptors promoting activation and the release of pro-inflammatory mediators 
including preformed histamine, heparin, tryptase and TNFa which cause the acute 
symptoms of an allergic response and newly synthesized mediators such as LTC4 , 
LTB4 , prostaglandin D2 and in the transcription of cytokines such as IL-4, IL-5, IL- 6  
and TNFa. (Table 3). A further six to 24 h later, a second round of symptoms (late- 
phase response) develops from the recruited inflammatory cells (Fig 1.2), in the 
lungs the late-phase reaction is believed to play a major role in the genesis of 
persistant asthma.
The clinical symptoms which manifest as a consequence of mast cell activation are 
dependent upon site of exposure, the immediate reaction in the skin presents as 
erythema, edema, and itch; in the lungs as cough, bronchospasm, edema and mucous 
secretion; and in the gastrointestinal tract as nausea, vomiting, diarrhea and 
cramping (Wedemeyer and Galli 2000).
1,3,2 Innate and acquired immunity
Mast cells are strategically placed between the internal and external environment 
and constitute one of the first lines of defence against microbial pathogens (Galli, 
Maurer et al. 1999). Mast cells express Toll-like receptors (TLR) (Bone marrow-
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derived mast cells (BMMCs) express TLR2, TLR4 and TLR6 ) which are a 
repertoire of innate immune pattern recognition receptors able to recognise bacterial 
proteins (Marshall 2004; Marshall and Jawdat 2004). Activation of mast cells 
through Toll-like receptors leads to release of a specific cytokine/lipid mediator 
profile responsible for protection against pathogen challenge. The cytokines 
(including TNFa. leukotrienes and others) released by mast cell activation recruit 
circulating leucocytes (including neutrophils) with bactericidal properties to the site 
of infection, (Marshall 2004; Marshall and Jawdat 2004).
Mast cells can also bind parasite-specific IgE, which leads to mast cell activation 
upon subsequent exposure to parasite antigen or the parasite itself. Activation leads 
to release of pro-inflammatory mediators as well as cytokines which can augment 
the adaptive immune response (Marshall 2004; Marshall and Jawdat 2004).
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Fig 1.2 The allergic cascade. Mast cell sensitisation occurs following initial exposure to antigens, and is a process in which CD4+ 
T cells release cytokines (IL-4 and IL-13) which promote B cell maturation and isotype switch from IgM production to IgE. This 
IgE is captured by IgE receptors on the mast cell surface. Secondary exposure to antigen leads to activation of mast cells and the 
release of pro-inflammatory mediators which cause the symptoms of allergic disease.
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1.4 Phosphoinositide 3-kinase
Eight PI(3)K isozymes have been identified and divided into 3 classes according to 
adaptor and substrate specificity. Receptor/ligand interactions trigger class I PI(3)Ks 
which phosphorylate membrane phosphatidylinositol-(4,5)-bisphosphate (PIP2 ) to 
form phosphatidylinositol-(3,4,5)-triphosphate (PIP3) which interacts with PIP3 - 
specific lipid binding modules belonging to the pleckstrin homology (PH) domain 
family within lipid effectors (Carpenter and Cantley 1996; Fruman, Meyers et al. 
1998; Vanhaesebroeck, Leevers et al. 2001). PIP3 promotes membrane recruitment 
which itself can lead to additional posttranslational modifications and further 
intermolecular interactions of its target proteins (Carpenter and Cantley 1996; 
Fruman, Meyers et al. 1998; Vanhaesebroeck, Leevers et al. 2001). PIP3 may also 
directly increase enzymatic activity by allosteric changes and/or relieving 
intramolecular inhibition within target proteins (Deane and Fruman 2004).
The nature of stimuli/receptors and regulatory mechanisms which activate class II 
PI(3)Ks is less well defined, in vitro data suggest that insulin, platelet-derived 
growth factor, integrin ligation can all activate class IIPI3K lipid kinase activity 
(Vanhaesebroeck, Leevers et al. 2001). Comprised of 3 members, PI(3)K-C2a, -C2p 
and -C2y, class II PI(3)Ks have a different substrate preference to class I and III (i.e. 
utilise phosphatidylinositol > other phosphoinositides), lack known adaptor/binding 
partners and are constitutively associated with membrane fractions and clathrin 
(Katso, Okkenhaug et al. 2001; Vanhaesebroeck, Leevers et al. 2001).
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Class III PI(3)K is comprised of Vps34p which is thought to be constitutively 
active, and to maintain a constant level of phosphatidylinositol-3-phosphate lipids. 
With a specific preference for phosphatidylinositol as a lipid substrate, Vps34p has 
been implicated in protein sorting to the vacuole/lysozyme and in other membrane 
transport events, including endocytosis and autophagy (Vanhaesebroeck, Leevers et 
al. 2001; Wymann and Marone 2005).
The PI(3)K signalling cascade is modulated by phosphoinositide phosphatase 
activity. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) has 
3’-phosphoinositide phosphatase activity and hydrolyses PIP3 into PIP2 whereas the 
SH2-domain-containing inositol phosphatase (SHIP), which has 5’-phosphoinositide 
phosphatase activity, produces phosphatidylinositol-(3,4)-bisphosphate, which can 
activate further signalling proteins downstream of PI(3)K (Katso, Okkenhaug et al. 
2001; Vanhaesebroeck, Leevers et al. 2001; Wymann, Zvelebil et al. 2003). Work in 
this thesis focused on the class I PI(3)K family.
1.4.1 Class IPI(3)K
The Class I PI(3)Ks are a family of heterodimeric molecular complexes comprised 
of a catalytic subunit associated with a regulatory adaptor. Further divided into IA 
and IB, the class IA PI(3)Ks signal downstream of tyrosine kinase pathways whereas 
class IB signal downstream of G-protein coupled receptors (GPCRs). The catalytic 
subunits of all class I members contain a Ras-binding domain and therefore also 
have the ability to interact with activated guanine-nucleotide-triphosphate (GTP)-
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bound Ras (Fruman, Meyers et al. 1998; Katso, Okkenhaug et al. 2001; 
Vanhaesebroeck, Leevers et al. 2001; Deane and Fruman 2004).
Three class IA ~110 kDa catalytic subunits encoded by distinct genes (PIK3CA: 
p i 10a, PIK3CB: p i 10p and PIK3CD: p i 108) have been identified and couple to 
one of 5 regulatory/adaptor subunits encoded by 3 genes (PIK3rl: p85a, p55a, 
p50a, PIK3r2: p85p and PIK3r3: p55y). The binding of p i 10 subunit with the 
regulatory adaptor appears to be constitutive with the adaptor subunit serving a dual 
purpose both as a mechanism for recruitment and to maintain stability of the p i 1 0  
subunit holding it in a low activity state (Fruman, Meyers et al. 1998; Katso, 
Okkenhaug et al. 2001; Vanhaesebroeck, Leevers et al. 2001; Deane and Fruman 
2004).
Whereas p i 10a and p i 1 Op appear to have a ubiquitous tissue distribution, the p i 108 
isoform of class LA PI(3)K has been shown to have a more restricted distribution 
primarily but not exclusively to the immune system (Chantry, Vojtek et al. 1997; 
Vanhaesebroeck, Welham et al. 1997; Fruman, Meyers et al. 1998; Katso, 
Okkenhaug et al. 2001; Vanhaesebroeck, Leevers et al. 2001; Deane and Fruman 
2004) (Fig 1.3).
Class IB consists of a single catalytic isoform p i lOy (PIK3CG) which associates 
with a p i01 (PIK3r5) or a newly described adaptor p84 (Suire, Coadwell et al. 2005; 
Wymann and Marone 2005). Expression of p i lOy is restricted mainly to the
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haematopoietic system, with lower levels expressed within smooth muscle, 
endothelial cells and cardiomyocytes (Wymann and Marone 2005).
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Fig 1.3 Class IA PI(3)Ks. Class IA PI(3)K is composed of five distinct regulatory subunits which couple to one of three distinct 
catalytic subunits. Class IA PI(3)Ks are recruited to phosphotyrosine residues within the sequence YxxM on phosphorylated 
receptors and adaptor proteins.
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1.4.2 Recruitment and activation o f class IA PI(3)K
Receptor/ligand interactions at the cell surface lead to tyrosine kinase signalling 
cascades which create phosphorylated tyrosines (pY) within YxxM motifs (where x 
is any amino acid) on activated growth factor receptors and adaptor proteins. These 
pY residues act as specific interaction sites for Src-homology 2 (SH2) domains of 
the class IA regulatory subunits.
All 5 class IA regulatory subunit isoforms (encoded by 3 genes) contain two SH2 
domains, separated by an inter-SH2 domain which serves as the docking site for the 
N-terminus of the class IA pi 10 subunits. p85a and p85(3 have additional N- 
terminal modules including a proline-rich region, SH3 domain and a Bcr-homology 
(BH) domain and can interact with Rho family GTPases including Rac (Fruman, 
Meyers et al. 1998; Katso, Okkenhaug et al. 2001; Vanhaesebroeck, Leevers et al. 
2001; Wymann, Zvelebil et al. 2003). Although class IA catalytic subunits contain 
Ras binding domains and can interact with GTP-bound Ras, recently it has been 
shown that these interactions can only take place in the context of a SH2-pY 
interaction (Jimenez, Hernandez et al. 2002).
1.4.2.1 Monomericp85 functions independently o f  p i  10
Biochemical analysis has determined that there is an excess of p85 regulatory
subunits within cells (-30% free p85), the purpose of these ‘monomeric’ p85
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subunits has not been fully determined (Sung, Sanchez-Margalet et al. 1994; Ueki, 
Fruman et al. 2002).
Part of the biological functions of ‘free’ p85 may be to drive lipid kinase 
independent functions. Evidence for this has been shown in T cells where it was 
found that expression of a membrane-localised p85 lacking the ability to associate 
with p i 10 (Ap85) potently upregulated interleukin-2 production in Jurkat and normal 
peripheral T cells. This feature of p85 was found to be Rac-dependent and is not 
inhibited by wortmannin (Kang, Schneider et al. 2002).
Monomeric p85 may also attenuate PI(3)K activity by competing with p85/pl 10 for 
pY residues (Sung, Sanchez-Margalet et al. 1994; Ueki, Fruman et al. 2002). 
Recently using a green fluorescence protein (GFP)-tagged p85a (EGFP-p85a) in the 
context of insulin like growth factor-1 (IGF-1) signalling, monomeric p85a has been 
shown to be involved in forming a sequestration complex with insulin receptor 
substrate-1 (IRS-1) and thereby acts as a mechanism for limiting IRS-1/PI(3)K 
signalling (Luo, Field et al. 2005). After 5-10 min of IGF-1 stimulation, monomeric 
p85 and IRS-1 assemble preferentially into large complexes in the cytosol which do 
not produce PIP3 . These interactions appear to depend on the NFL-terminal SH3 and 
BH domains of p85a. Indeed, p55a and p50a which lack these domains did not 
share this function with p85a (Luo, Field et al. 2005). Furthermore the sequestration 
mechanism for limiting PI(3)K activity also appears to be stimulus-specific and was
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not observed upon platelet derived growth factor (PDGF) stimulation of cells (Luo, 
Field et al. 2005).
1.4.2.2 GPCR modulation ofPI(3)K  activity
A further mechanism for modulating the PI(3)K pathway as been described and 
relates to GPCR signalling. Biochemical evidence has shown that the pi 10p isoform 
of class IA PI(3)K can interact with the py subunits of Gi/ 0 family GPCRs. In vitro, 
lipid kinase activity of p i 10(3 can be synergistically increased by a pY peptide in 
combination with Gpy. To date this feature of class LA PI(3)K appears to be 
exclusive to p i 1 0 p as experimental data suggests that p i 1 0 a  and p i 108 appear 
insensitive to this type of stimulation (Katada, Kurosu et al. 1999; Maier, Babich et 
al. 1999). In contrast to activating class LA PI(3)K, GPCR (Gaq subunit) signalling 
has also been shown to selectively antagonise pi 1 0 a  lipid kinase activity with no 
effect on pi 10p kinase activity (Ballou, Lin et al. 2003). The physiological role of 
the interactions of class IA with GPCRs remains unclear but may have important 
implications for diverse immunological responses including leukocyte chemotaxis 
and activation (Sadhu, Dick et al. 2003; Puri, Doggett et al. 2004; Condliffe, 
Davidson et al. 2005; Puri, Doggett et al. 2005; Thomas, Smith et al. 2005).
1.4.3 Recruitment and activation o f class IB PI(3)K
Ligand-triggered activation leads to translocation of p i lOy to activated GPCRs 
where it is stimulated by its interaction with Py subunits (Stoyanov, Volinia et al.
43
Chapter 1_____________________________________________________ Introduction
1995; Stephens, Eguinoa et al. 1997). Work to identify the relationship between the 
plOl adaptor protein and the pi lOy subunit has revealed that unlike class IA 
members for which the p85 regulatory subunit is essential for pY interactions, p i lOy 
can be directly stimulated by activated Gpy (Maier, Babich et al. 1999). The purpose 
of the plOl subunit appears to be important for lipid substrate specificity (Maier, 
Babich et al. 1999). Whereas p i lOy can interact with and be activated by GpY 
subunits directly, under these conditions pi lOy converts phosphatidylinositol 
primarily into phosphatidylinositol-3-phosphate and very small amounts of 
phosphatidylinositol-(3,4,5)-triphosphate, however within a heterodimeric complex 
with p 101, p i lOy primarily catalyses the formation of phosphatidylinositol-(3,4,5)- 
triphosphate (Maier, Babich et al. 1999).
Similar to class IA PI(3)Ks, pi lOy also contains a Ras binding domain, however 
although some progress has been made in understanding how class IA interact with 
this important oncogene the mechanism and importance of p i lOy interactions with 
Ras remain as yet not well-defined.
1.4.4 PI(3)K adaptor proteins
PI(3)K activity is recruited to a large array of activated receptors, many of these are 
tyrosine kinase receptors able to directly interact with the SH2 domains of the class 
IA regulatory subunits (Kit, PDGF-receptor etc). However there are an equally large 
number of receptors which are reliant on PI(3)K activity but unable to directly 
interact with these SH2 domains (including for example the B-cell antigen receptor, 
FcsRI, interleukin-3 receptor etc). These receptors rely on recruiting adaptor
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proteins which serve as scaffolds that link PI(3)K activity to activated receptors 
(Wymann, Zvelebil et al. 2003).
Adaptor protein interactions with class IA PI(3)K are reliant on YxxM motifs which 
are phosphorylated either directly (via intrinsic receptor tyrosine kinase activity) or 
indirectly via non-receptor tyrosine kinases (e.g. Jak, Syk, Fyn). The insulin receptor 
substrate (IRS 1-4) and Grb2-associated binder (Gab 1-3) adaptor proteins are 
typical of this type of adaptor (Wymann, Zvelebil et al. 2003). Both contain multiple 
YxxM motifs and PnVinteracting PH domains which can facilitate membrane 
translocation (Razzini, Ingrosso et al. 2000; Rodrigues, Falasca et al. 2000). Loss of 
Gab or IRS adaptor proteins through genetic modification leads to attenuation of 
receptor (and pY)-associated PI(3)K activity (Myers, Backer et al. 1992; Gu, Saito et 
al. 2 0 0 1 ).
1.5 Gene-targeting of PI(3)K subunits
Gene targeting has been used to as a tool for dissecting molecular function from in 
vitro cell-based systems through to whole organisms. Recently several gene-targeted 
PI(3)K genetic models been described that have helped to dissect the PI(3)K 
signalling pathway within the immune system. This section provides a summary of 
genetic models and brief details relating to published immunological phenotypes in 
cells other than mast cells (the latter will be discussed separately).
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1.5.1 Regulatory subunit knock-out (KO) mice ( ‘p85 KO mice9)
Of the five class IA regulatory/adaptor proteins all but one (PIK3r3, encoding p55y) 
have been subjected to gene targeting and are commonly referred to as ‘p85 KO 
mice’.
1.5.1.1 Complexities o f  targeting regulatory subunits
The p85 regulatory subunits are essential for maintaining stability of the PI(3)K 
complex (Yu, Zhang et al. 1998). Genetic disruption of genes which encode the 
regulatory subunits leads to a concomitant decrease in p i 1 0  expression proportional 
to the reduction in the relative level of regulatory adaptor(s) (Vanhaesebroeck, Ali et 
al. 2005). Although p85 KO mice have a number of immunological phenotypes 
thought to be a consequence of this reduction in V\{3)-kinase activity, the 
interpretation of these phenotypes is complicated by evidence of deregulation within 
the class IA compartment. Apart from disrupting p i 10 expression it appears that 
genetic manipulation of the regulatory adaptor compartment can also alter the 
expression of the remaining adaptor subunits leading to upregulation of the non­
targeted adaptor proteins (Vanhaesebroeck, Ali et al. 2005).
The p85 regulatory subunits may also influence the expression, stability and 
recruitment of other important proteins interacting with the PI(3)K pathway, 
including the phosphatases PTEN and SHIP. Previous work in mouse embryonic 
fibroblasts (MEFs) has shown that PTEN protein expression is sensitive to p85 
levels. Heterozygous p85a null mouse embryonic fibroblasts (MEFs) been reported
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to have a two-fold increase in PTEN expression which was not observed in 
homozygous p85a null cells (Ueki, Fruman et al. 2002). It is possible that this 
deregulation of PTEN expression is related to the in vitro transformation of the 
embryonic fibroblasts by introduced oncogenes.
SHIP is known to associate with p85 upon FcyRII activation which can co-aggregate 
with the B cell receptor and the mast cell antigen receptor upon antigen crosslinking 
(Gupta, Scharenberg et al. 1999). The impact of regulatory subunit deletions on the 
SHIP or PTEN phosphatases in immunological cells has not been assessed to date.
Overall the data relating to immunological phenotypes of the various p85 KO mice 
(outlined below) strongly suggest that class IA PI(3)K has both positive and negative 
roles in immunological function.
1.5.1.2 p 8 5 a  is essential fo r  B cell development and function
Disruption of p85a, which appears to be the most abundant regulatory subunit, leads 
to impaired B cell development and function (Fruman, Snapper et al. 1999; Suzuki, 
Terauchi et al. 1999; Suzuki, Matsuda et al. 2003; Hess, Donahue et al. 2004). B 
cells isolated from p85a KO mice have a severe attenuation in antigen receptor- 
stimulated proliferation and an increased propensity towards apoptosis. Proliferation 
in response to the polyclonal B cell mitogens lipopolysaccharide (LPS) and anti- 
CD40 is also impaired but to a lesser extent.
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In vivo p85a deletion leads to partial block in early B cell development at the pro-B 
to pre-B transition, a marked reduction in the number of mature splenic B cells, and 
a nearly complete absence of the B1 subset of mature B cells. These mice also fail to 
mount an effective antibody response to T-independent type II antigens.
Disruption of the PIKSrl appears to have no impact on T cell development and 
proliferation (Fruman, Snapper et al. 1999; Suzuki, Terauchi et al. 1999).
1.5.1.3 Class I  A PI(3)K maintains Thl/Th2 balance through dendritic 
cell cytokine production
Class IA PI(3)Ks also appear to have an important role in maintaining the Thl/Th2 
balance through its negative role in dendritic cell (DC) function. In vitro LPS- 
stimulated DCs isolated from p85a KO mice have a modest reduction in PI(3)K 
activity (as assessed by protein kinase B (PKB) phosphorylation) with an associated 
increase in IL-12 production. Constitutive overproduction of IL-12 (the nature of the 
in vivo stimulus has not been identified) leads to an in vivo Thl skew. The 
consequence of this altered Thl/Th2 balance include increased resistance to 
Leishmania major infection (which is dependent upon a Thl response) but increased 
susceptibility to infections that require a host Th2 response (such as Strongyloides 
venezuelensis parasite infection) (Fukao, Tanabe et al. 2002; Fukao, Yamada et al. 
2002).
48
Chapter 1_____________________________________________________Introduction
1.5.1.4 p85/3 is a negative regulator o f  T cell function 
p85p KO mice do not appear to have immunological defects severe as those reported 
in the p85a KO. This may in part be a result o f compensation by the more dominant 
p85a isoform, however analysis of T cells from the p85(3 KO suggests that there 
maybe qualitative as well as quantitative differences between p85a and 
p85p (Deane, Trifilo et al. 2004). T cells lacking p85(3 are hyper-responsive to anti- 
CD3 stimulated proliferation and survival, even though PI(3)K activity (as assessed 
by PKB phosphorylation) appears unaffected (Vanhaesebroeck, Ali et al. 2005). The 
reason for this difference is unclear but maybe a consequence of the loss of as yet 
unknown p85p-specific protein-protein interactions which play a negative role in T 
cell responses lost upon of deletion of p85p (Deane, Trifilo et al. 2004).
1.5.2 Catalytic subunit, ‘p i  10’ KO mice
All class I PI(3)K pi 10 subunits have been subjected to gene targeting. Disruption of 
p i 1 0 a  or p i 1 0 p is embryonic lethal and has precluded analysis of these isoforms 
within the immune system (Bi, Okabe et al. 1999; Laffargue, Calvez et al. 2002).
The remaining class I isozymes p i 108 and p i lOy have been targeted using different 
genetic strategies and have all produced viable mice with various immunological 
defects (Hirsch, Katanaev et al. 2000; Li, Jiang et al. 2000; Sasaki, Irie-Sasaki et al. 
2000; Clayton, Bardi et al. 2002; Jou, Carpino et al. 2002; Okkenhaug, Bilancio et 
al. 2002; Patrucco, Notte et al. 2004).
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1.5.2.1 p i  1 0 8 is critical to the adaptive immune response
B cells in which p i 105 has been genetically inactivated or deleted have defects in 
development, activation and antibody response similar to those reported in p85a KO 
mice (Clayton, Bardi et al. 2002; Jou, Carpino et al. 2002; Okkenhaug and 
Vanhaesebroeck 2003). pi 108 also appears to have a role downstream of the T cell 
antigen receptor (TcR). Purified CD4+ T cells isolated from pi 108D910A/D910A mice 
expressing a catalytically inactive form of pi 108 have a reduced anti-CD3- 
stimulated proliferation. CD28 costimulation provides an important second signal in 
TcR-regulated cytokine production, proliferation and survival. The intracellular 
domain of CD28 contains a specific tyrosine residue (Y710) that allows CD28 to 
directly couple to Class IA PI(3)K. Mutation of CD28 such that it can no longer 
interact with class IA PI(3)K (Y170F) specifically disrupts CD28-mediated survival 
signals without affecting CD28-dependent proliferation or IL-2 secretion 
(Okkenhaug, Wu et al. 2001). Consistent with these results, T cell defects in IL-2 
production and anti-CD3-stimulated proliferation in p i 1 o5D9IOA/D910A mice can be 
overcome, or even enhanced by CD28 costimulation (Okkenhaug, Bilancio et al. 
2002).
1.5.2.2 p i  105 is important fo r  neutrophil responses
pi 108 is part of the class LA family of PI(3)K which are couple via regulatory 
adaptor subunits to specific phosphotyrosine sequences (within the consensus 
YxxM) downstream of tyrosine kinase signaling; therefore in theory p i 108 does not
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have the capacity to directly interact with GPCR signaling, this is in contrast to 
p 11 Oy which contains a G(3y interaction domain. However there are reports that 
p i 108 may also play a role in neutrophil trafficking and activation stimulated by 
chemokine molecules such as formyl-Met-Leu-Phe (fMLP) which activates GPCRs. 
Pharmacological blockade or genetic deletion of p i 108 leads to attenuated fMLP- 
stimulated neutrophil activation, LT (leukotriene)B4 -induced migration and 
neutrophil accumulation in a model of LPS-induced acute lung injury (Puri, Doggett 
et al. 2004). p i 108 appears to participate not only in leukocyte migration to chemo- 
attractants but also within endothelial cells where it is important in tumour necrosis 
factor-a (TNFa)-stimulated E-selectin-dependent adhesion of neutrophils to the 
vascular endothelium (Puri, Doggett et al. 2005).
It is important to mention that that the role of p i 108 within neutrophil activation and 
chemokine/GPCR-directed migration is contentious, amongst other because there is 
no biochemical evidence to suggest that p i 108 couples directly to chemokine or 
GPCR signalling. It is possible though that pi 108 indirectly couples to GPCR- 
induced signalling and biological responses (see also paragraph 1.5.3.3).
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1.5.2.3 p i  lO y is critical fo r  driving PI(3)K-dependent GPCR chemotaxis 
and oxidative burst
Inflammation involves the activation of leukocytes and the release of a host of pro- 
inflammatory mediators including chemokines which recruit other immune effectors 
and thereby exacerbate the immune response.
Leukocytes sense and migrate directionally following gradients of chemo-attractant 
(many of which signal through GPCRs) towards sites of inflammation. The sense of 
direction is pivotal for cell migration, events at the leading edge of a cell are clearly 
distinct from those at the trailing edge; subcellular localisation is essential for 
defining morphological polarity during chemotaxis (Procko and McColl 2005). The 
process of chemotaxis requires an ordered projection o f a pseudopod from the cells 
leading edge, with the involvement of massive cytoskeletal reorganisation and co­
ordinated integrin attachment and detachment at the leading and trailing edges of a 
cell. Although the precise details remain unclear the involvement of PI(3)K activity 
in the process of chemotaxis is overwhelming. In cells stimulated with 
chemoattractants the net PI(3)K (PIP3 gradient) activity is confined to the leading 
edge of the cell. Chemokine receptors signall through GPCRs and therefore it is 
expected that PI(3)K activity downstream of these receptors would most likely be 
provided by the p i lOy isoform of PI(3)K (Stephens, Ellson et al. 2002).
p i lOy couples specifically to Gai type GPCR receptors and has been identified as 
critical for leukocyte pathfinding. Chemokine activation of p i lOy generates a PIP3
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gradient which polarizes a cell towards the chemokine stimulus; this PIP3 gradient 
has been identified to be of crucial importance in directing the migration of 
leukocytes towards chemoattractants. The chemotactic migration of isolated 
neutrophils, macrophages and eosinophils from p i lOy null mice is substantially (but 
not completely) impaired (Hirsch, Katanaev et al. 2000; Sasaki, Irie-Sasaki et al. 
2000; Pinho, Souza et al. 2005; Thomas, Smith et al. 2005).
Apart from its critical role in immune cell chemotaxis, p i lOy has an important role 
in GPCR-stimulated leukocyte respiratory burst in neutrophils and mast cells 
(discussed later, see section 1.8.1) (Hirsch, Katanaev et al. 2000; Laffargue, Calvez 
et al. 2002; Condliffe, Davidson et al. 2005). The defect in mast cell activation is 
thought to be responsible for resistance to systemic anaphylaxis challenge directed 
through the FcsRI receptor, p i lOy also appears to be important for T cell 
proliferation and survival both of which are reduced in p i lOy null mice (Sasaki, Irie- 
Sasaki et al. 2000).
p i lOy null mice have been found to be less responsive in several disease models 
including LPS-induced acute injury (accumulate substantially reduced numbers of 
leucocytes), allergic pleurisy (impaired eosinophil accumulation and survival), 
delayed type sensitivity (defects in dendritic cell homing to peripheral lymph nodes) 
and rheumatoid arthritis (defective neutrophil migration). In most if  not all of these 
disease models a defect in leukocyte directional migration (which leads to severe 
defects in leukocyte homing and infiltration) is central to the reduced responsiveness
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of p i lOy null mice (Hirsch, Katanaev et al. 2000; Sasaki, Irie-Sasaki et al. 2000; Del 
Prete, Vermi et al. 2004; Camps, Ruckle et al. 2005; Pinho, Souza et al. 2005).
Recently it has been shown that p i lOy expressed within the endothelium has an 
important role in assisting the trafficking of leukocytes to sites of inflammation, 
p i lOy null mice reconstituted with wild-type (WT) neutrophils retain a 45% 
reduction in neutrophil accumulation following acute lung injury. WT neutrophils 
have a 70% reduction in attachment and a 17-fold increase in rolling velocities on 
p i lOy null microvessels in response to TNFa. The defect is thought to relate to a 
deficiency in selectin-mediated adhesion and no doubt contributes towards the 
severity of the defects in neutrophil accumulation reported in p i lOy null mice 
following acute lung injury and most likely contributes to the reduced 
responsiveness of p i lOy null mice in the disease models mentioned above (Puri, 
Doggett et al. 2005).
1.5.3 PI(3)K isoform-specific functions
1.5.3.1 Regulatory isoforms have distinct functions
Class IA regulatory iso forms are the product of three distinct genes which encode 
five different adaptor proteins (Vanhaesebroeck, Leevers et al. 2001). Regulatory 
adaptors all have a common pi 10 binding site but have distinct N-terminal regions 
which allow for additional protein-protein interactions which may differ between the 
p85 isoforms (Vanhaesebroeck, Leevers et al. 2001).
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Deletion of p85a, most likely the most abundant regulatory isoform, leads to 
attenuated B cell proliferation and survival but appears to leave T cell responses 
intact (Fruman, Snapper et al. 1999; Suzuki, Terauchi et al. 1999; Suzuki, Matsuda 
et al. 2003; Hess, Donahue et al. 2004). In contrast p85(3 appears non-essential for B 
cell function but is necessary for modulating T cell responses. Deletion ofp85p 
enhances T cell proliferation and survival (Deane, Trifilo et al. 2004).
Class IA regulatory subunits have no kinase activity and there is no data to suggest 
that they specifically couple to distinct p i 10 subunits, therefore p85 specific 
functions uncovered in these genetic studies are most likely the result of differential 
protein-protein interactions between the various regulatory subunits 
B and T cell antigen receptors, unlike tyrosine kinase receptors, have no direct 
PI(3)K binding sites and PI(3)K activity is recruited to these receptors through 
adaptors proteins. It is known that B and T cell receptors recruit different protein 
tyrosine kinases which phosphorylate distinct adaptor proteins upon activation.
It is not known is whether these adaptor proteins associate with different p85 
species. This is an area which requires further investigation.
1.5.3.2 p i  108 -specific functions
B cells are extremely senstivive to deletion or inactivation of the p i 108 subunit. 
Several reasons including quantitative and qualitative differences between the p i 10 
subunits may account for this sensitivity, p i 108 may be the ‘dominant’ class LA 
PI(3)K expressed in B cells, as a consequence this may mean that PI(3)K dependent
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receptors such as the BCR, in the absence of p i 108 may not have access to 
sufficient PI(3)K to reach a PIP3 threshold in order to drive a functional response 
(Chantry, Vojtek et al. 1997; Vanhaesebroeck, Welham et al. 1997) (Clayton, Bardi 
et al. 2002; Jou, Carpino et al. 2002; Okkenhaug, Bilancio et al. 2002). Qualitative 
differences between pi 1 0  subunits may also be of importance including differences 
in activation by Ras or intrinsic differences in protein kinase 
activity(Vanhaesebroeck, Higashi et al. 1999).
1.5.3.3 Cooperation between Class IP I(3)K  in neutrophil activation and 
migration
Genetic data indicate that although p i 108 and pi 10y have distinct roles in leukocyte 
biology which is primarily a consequence of the different pathways (tyrosine kinase 
and GPCR signalling) to which these distinct PI(3)K isoforms couple, there is 
evidence to suggest that p i 108 and p i lOy may have overlapping roles in certain 
leukocyte responses such as neutrophil activation and chemotaxis (Puri, Doggett et 
al. 2004; Puri, Doggett et al. 2005).
Chemokines activate GPCR receptors and therefore any PI(3)K-dependent functions 
through such receptors are thought to be translated solely through the p i lOy isoform 
(Wymann, Bjorklof et al. 2003). p i 10y null neutrophils have an attenuated 
chemotaxis which leads to substantially reduced accumulation of these cells upon 
acute lung injury in p i lOy null mice. Part of the mechanism behind these neutrophil
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defects appears to be impaired Rac activation and F-actin accumulation at the 
leading edge.
Analysis of p i 108-deficient neutrophils indicates that this GPCR-insensitive PI(3)K 
isoform may also in some way have a role chemokine responses thought to be 
p i lOy-dependent. Chemokine-stimulated p i 108 null neutrophils have impaired 
chemotaxis and activation (Sadhu, Dick et al. 2003); however unlike in p i lOy null 
cells, F-actin synthesis was not blocked in these cells suggesting that p i 108 may 
affect the same functional responses but in a different way to p i lOy (Sadhu, Dick et 
al. 2003).
Recently published data provides a plausible hypothesis to explain how both of these 
distinct PI(3)Ks can influence the same phenomenon by working differently within 
the same pathway. It is now thought that GPCR stimulation can activate both class 
IB p i lOy and class IA PI(3)K isoforms sequentially in a two-step process. Initial 
activation of GPCR receptors is thought to activate a burst of p i lOy-dependent 
PI(3)K activity which recruits the PH domain containing guanine-nucleotide 
exchange factor p-Rexl. Recruitment of pRexl is thought to activate Rac which can 
then facilitate the activation of p85-bound class IA PI(3)K isoforms which can then 
further augment PI(3)K activity. There is also evidence for induction of global 
tyrosine phosphorylation upon GPCR stimulation, which might then lead, in one 
way or another, to activation of class IA PI3K activity (Condliffe, Davidson et al.
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2005). Thus neutrophil chemotaxis and activation may require both class IA and IB 
working together in distinct ways.
1.6 Pharmacological interference with PI(3)K 
function
The availability of pharmacological tools has greatly facilitated dissection of the 
PI(3)K signalling pathway. Wortmannin and LY294002, two first-generation 
structurally distinct broad spectrum PI(3)K inhibitors have been used widely for this 
purpose (Fig 4). Both compounds target the ATP binding pocket within the kinase 
domain and have little selectivity for distinct PI(3)K isoforms (Knight, Chiang et al. 
2004). Wortmannin is more potent than LY294002 and has an IC50 value for PI(3)K 
within the low nanomolar range and interacts in a covalent manner with the catalytic 
site (alkylates a Lys within the ATP-binding site). LY294002 in contrast is an ATP- 
competitive inhibitor with potency within the low micromolar range. Both 
compounds have low specificity at higher concentrations and are able to inhibit a 
number of other protein kinases (Arcaro and Wymann 1993; Thelen, Wymann et al. 
1994; Ward, June et al. 1996; Wymann, Bulgarelli-Leva et al. 1996; Stein and 
Waterfield 2000; Knight, Chiang et al. 2004).
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Wortmannin LY294002
Fig 4. The broad spectrum PI(3)K inhibitors wortmannin and LY294002
Second generation PI(3)K inhibitors have increased specificity and potency and 
include a range of compounds which have selectivity for one or more of the class I 
PI(3)K family and are described in a recent review (Prestwich 2004). Recently a 
pharmacological inhibitor (IC87114) which selectively targets the p i 108 PI(3)K has 
been described (world patent no. WO0181346) (Fig 5). IC87114 has been described 
as an ATP-competitive inhibitor able to selectively inhibit p i 108 activity. The IC50 
of IC87114 for p i 108 inhibition is 0.5 pM whereas the IC50  values for p i 10a, 
p i 10(3 and p i 10y are reported to be >100, 75, and 29 pM, respectively. Thus 
IC87114 is 58-fold more selective for pi 108 over p i lOy, and over 100-fold selective 
relative to p i 10a and p i 10p (Sadhu, Masinovsky et al. 2003).
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Fig 5. The p i 1 OS-selective inhibitor IC87114
1.7 Role of PI(3)K in mast cell homeostasis
Various approaches have been used to define the role of PI(3)K in mast cell 
homeostasis including pharmacological inhibitors, expression of dominant- 
negatively acting proteins and gene targeting. Table 4 lists some phenotypes 
reported from the various gene targeted PI(3)K mutant mice within a mast cell 
context.
1. 7.1 The Kit receptor is essential for mast cell homeostasis
The receptor tyrosine kinase Kit is critical to mast cell homeostasis. Loss of Kit 
expression or reduction in Kit kinase activity leads to severe disruption of tissue 
mast cell numbers. Kit is activated by receptor crosslinking by its cognate ligand
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SCF. Activation is followed by receptor auto-phosphorylation on tyrosine residues 
providing docking sites for specific SH2 domain-containing proteins which once 
active promote cell proliferation and survival (Metcalfe, Baram et al. 1997).
The Kit receptor is capable of direct and indirect interactions with PI(3)K. Two sites 
which facilitate Kit interaction with PI(3)K are the juxtamembrane Src binding sites 
(Y567 and Y569) and the more distal direct PI(3)K binding site Y719 (Fig 1.6). 
Other interactions of Kit with PI(3)K are possible through adaptor proteins such as 
Grb2-associated binder protein (Gab2) (Ronnstrand 2004).
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SHP1
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Y-936
Fig 1.6 The (human) Kit receptor.
1.7.2 Kit/PI(3)K interactions maintain the homeostasis o f  (a) mast cell 
subset(s)
Genetic mutation of Y567 and Y569 to phenylalanine (KitFFmice) within the 
juxtamembrane of the Kit receptor prevents the binding of Src family protein 
tyrosine kinase (and other interacting partners such as the tyrosine phosphatases 
SHP-1 and SHP-2). KitFF mice have a severe reduction in all mast cell populations
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including those within the peritoneum, skin and gastrointestinal tract (Kimura, Jones 
et al. 2004). The juxtamembrane region of the Kit receptor is often referred to as the 
regulatory site as such mutations within this region severely attenuate receptor 
tyrosine phosphorylation and can effect the binding of all SH2 domain containing 
proteins including p85.
In contrast genetic mutation which selectively interfere with Kit/PI(3)K interactions 
either through site-directed mutagenesis of the PI(3)K binding site, Y719
Y719F Y719F(Kit /Kit mice) or by deletion of p85a lead to tissue site-selective loss of 
mast cell populations, thus Kit/PI(3)K interactions maintain the homeostasis of (a) 
specific mast cell subset(s) within the peritoneum and the gastrointestinal tract 
(Kissel, Timokhina et al. 2000; Fukao, Yamada et al. 2002).
1,7,3 Two convergent pathways control Kit-dependent mast cell 
homeostasis
Two pathways which maintain Kit-dependent mast cell homeostasis are the PI(3)K 
and Jun N-terminal kinase (JNK) pathways. Overall molecular and genetic work 
indicates that the JNK pathway is critical for SCF-dependent proliferation but 
dispensable for protection from apoptosis which is under the control of the 
PI(3)K/PKB pathway (Timokhina, Kissel et al. 1998; Lu-Kuo, Fruman et al. 2000; 
Fukao, Yamada et al. 2002).
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Data from cells expressing mutant Kit receptors which can no longer interact with 
Src PTK (KitY567F), PI(3)K (KitY719F) or both (KitY5 6 7F/KitY719F) have shown that 
each of these pathways which partially contribute towards SCF-induced proliferation 
and protection from apoptosis converge to activate (via Rac) JNK (Timokhina,
Kissel et al. 1998). A more direct interference with the JNK pathway by expressing 
dominant negative Racl (RacN17) or JNK confirms these data but indicates that the 
JNK pathway does not have a role in SCF-dependent protection from apoptosis 
(Timokhina, Kissel et al. 1998).
The importance of PI(3)K to SCF-induced proliferation and protection from 
apoptosis has also been confirmed by gene-targeting. Genetic mutation of tyrosine- 
719 leads to complete abrogation of Kit associated PI(3)K and a concomitant 
reduction in PKB phosphorylation. BMMC derived from KitY71 9F/KitY719F mice have 
a substantial reduction (40-60%) in SCF-induced proliferation and protection from 
apoptosis. Analysis of signalling pathways confirms that PI(3)K activity through 
Y719 is important for JNK activity (which is reduced by 90%) (Kissel, Timokhina et 
al. 2 0 0 0 ).
Gene-targeted deletion of regulatory adaptors prevents PI(3)K recruitment to 
activated receptors. Genetic deletion of gene-products encoded by PIK3rl indicates 
the Kit receptor is dependent upon PI(3)K to drive both proliferation and survival. 
These data also indicate that the p85a regulatory subunit may have additional 
features utilised by the Kit receptor which are independent of PI(3)-kinase activity.
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SCF-stimulation of BMMCs derived from p85a null mice (in which p55a and p50a 
remain intact) have a substantial reduction in JNK activity (60% reduction) but only 
a minor reduction in PKB phosphorylation (30% reduction), these signalling defects 
are thought to explain the severe reduction in proliferation (a consequence of a 
reduction in JNK activity) in the absence of a significant impact on SCF-dependent 
protection from apoptosis (consequence of a minor defect in PKB) (Fukao, Yamada 
et al. 2002). These conclusions are strengthened by data from a separate study which 
utilised mast cells derived from a pan-p85a KO (lacking all PIK3rl gene-products) 
which reported a similar reduction in SCF-induced proliferation as well as a 
reduction in SCF-dependent protection from apoptosis which correlated with the 
more severe attenuation of PKB phosphorylation (a consequence of a more severe 
disruption of Kit associated PI(3)K activity) (Lu-Kuo, Fruman et al. 2000).
These data indicate that the JNK and PKB pathways may have a differential 
sensitive to perturbations in PI(3)K activity. Attenuation of JNK pathway (critical 
for SCF-induced proliferation) requires only a minor perturbation of PI(3)K activity 
whereas in contrast the PKB pathway (which maintains SCF-dependent mast cell 
survival) requires less PI(3)K input and therefore requires a more robust disruption 
of PI(3)-kinase activity.
It is also possible that the JNK pathway may be particularly sensitive to deletion of 
the full length p85a which has unique properties including a N-terminal BH domain
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able to interact with Rho family GTPase such as Rac. The nature and the 
physiological relevance of these interactions are unclear (Deane and Fruman 2004).
The importance of Rac to SCF-dependent responses has been shown by genetic 
deletion of the haematopoietic restricted Rac2 GTPase. Rac2 null mast cells have a 
profound attenuation of SCF-induced proliferation, survival, and migration. Rac2 
null mast cells also have a complete abrogation of PKB phosphorylation indicative 
that loss of Rac2 leads to a profound inhibition of PI(3)K activity. This genetic study 
places Rac upstream of or parallel to PI(3)K(Yang, Kapur et al. 2000).
KitY7 1 9F/KitY719F BMMCs have a 90% reduction in JNK activity (Kissel, Timokhina 
et al. 2000). The disruption of Y719 in KitY7 1 9F/KitY719F BMMCs leads to abrogation 
of p85a and p85(3 association with the Kit receptor. It is therefore possible that this 
mutation completely abrogates all p85-dependent Rac interactions with the Kit 
receptor. Deletion of p85a-only (one of two regulatory subunits with a BH domain) 
reflects a minor perturbation of receptor associated PI(3)K activity (30% reduction 
in PKB phosphorylation) but it represents a substantial reduction in a Rac interacting 
partner. The impact of this disruption is a significant (but not total) reduction in (Rac 
dependent?) JNK (60% reduction) activity (Fukao, Yamada et al. 2002; Tan, 
Yazicioglu et al. 2003). The remaining PI(3)K-dependent JNK activity (which can 
be reduced up-to 90% by mutating Y719) maybe mediated through p85p.
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Overall the data indicate that the direct PI(3)K binding site on the Kit receptor may 
be more than a mechanism for activating PI(3)K it may also act as a mechanism to 
allow Kit to interact with (via p85a and p85(3) the Rac GTPase and thereby activate 
the JNK pathway. It is also possible that PI(3)K may contribute to Rac activation by 
recruiting PI(3)K-dependent guanine nucleotide exchange factors (GEFs) which may 
augment Rac activation. A potential model for these interactions is summarised in 
Fig 1.7.
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Fig 1.7 Kit receptor-associated PI(3)K activation. PI(3)K/Rac interactions drive 
mitogenic and survival signals downstream of the Kit receptor.
1.7.4 Kit can recruit Gab2 adaptor associated PI(3)K activity
Interactions between PI(3)K and Kit can be direct and indirect, the latter for example 
via adaptor proteins such as Gab2 which contain multiple YxxM motifs and can 
recruit a large quantity of PI(3)K activity to receptor complexes. These associations 
provide receptors access to a larger pool of PI(3)K than the direct binding sites. Loss
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of Gab2 leads to similar in vivo mast cell tissue distribution defects to those reported 
in the p85a KO (Gu, Saito et al. 2001; Nishida, Wang et al. 2002). BMMCs derived 
from the Gab2 null mice have a partial defect in SCF-induced proliferation (only at 
higher concentrations of SCF) and PKB phosphorylation (Nishida, Wang et al. 
2002).
The data from KitY7 1 9F/KitY719F BMMCs suggest that mutation of Y719 may lead to 
complete abrogation of PI(3)K association with the Kit receptor including that of 
Gab2 (although this has not been formally tested). These data can be reconciled if 
Kit receptor-associated PI(3)K activity consists of two temporally distinct phases, 
the first ‘wave’ of PI(3)K activity recruiting the second which maybe coupled to 
adaptors such as Gab2 which contains a PH domain able to interact with PIP3 (Fig 
1.8). However this hypothesis requires qualification. As there is no detailed kinetic 
analysis of SCF-stimulated PI(3)K association or PKB activation (assessed only 
after 5 min) in the BMMC derived from KitY7 1 9F/KitY7l9F, it remains possible that 
this mutation does not block the Gab2-recruited PI(3)K activity which may have 
been recruited at later time-points.
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PI(3)KPI(3)K *l pP K B
Fig 1.8 PI(3)K dependent recruitment of Gab2-associated PI(3)K activity. The
initial *wave ' ofY719 associated PI(3)K activity may recruit a second phase o f 
Gab2-associated PI(3)K activity to augment Kit-dependent responses. Arrows 
indicate the impact on PKB phosphorylation ofgenetic mutation o f  the direct PI(3)K 
binding site (Kit-tyrosine 719) or deletion o f  the Gab2 adaptor protein.
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1.8 Role of PI(3)K in FcsRI mast cell activation
Mast cell activation leads to a co-coordinated cascade of events culminating in the 
exocytosis of preformed and newly synthesised mediators. IgE-dependent antigen- 
specific responses are directed through FcsRI, a heterotetrameric immunoglobulin 
receptor composed of (1) a ligand binding FcsRIa chain which binds IgE, (2) a 
signal amplifying FcsRip chain containing two immunoreceptor tyrosine-based 
activation motifs (ITAMs) and (3) two disulphide-linked FcsRIy chains critical to 
signal propagation (Kinet 1999; Rivera, Cordero et al. 2002; Blank and Rivera 
2004).
Receptor aggregation initiates a protein tyrosine kinase signalling cascade leading to 
the activation of two parallel pathways within distinct intracellular compartments, 
nucleated by the adaptor proteins Linker for activation of T cells (LAT) and Gab2, 
both of which are known to associate with PI(3)K (Fukao, Terauchi et al. 2003; 
Blank and Rivera 2004; Deane and Fruman 2004). Cross-talk between these 
compartments both augments and modulates each pathway and the overall 
exocytosis process (Blank and Rivera 2004).
1.8,1 Calcium mobilisation and protein kinase C activation are pre­
requisite for degranulation
Two pre-requisite events essential for optimal exocytosis and cytokine production 
are cytosolic calcium mobilisation and activation of protein kinase C (PKC), both of
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which known to be influenced by PI(3)K activity (Rivera, Cordero et al. 2002; 
Fukao, Terauchi et al. 2003; Blank and Rivera 2004; Deane and Fruman 2004).
Receptors that are capable of stimulating the release of intracellular calcium induce 
the tyrosine phosphorylation of phospholipase Cyl (PLCyl) and PLCy2, resulting in 
the generation of the second messengers inositol-1,4,5-triphosphate (IP3 ) and 
diacylglycerol (DAG) (Zhang, Berenstein et al. 1996; Scharenberg and Kinet 1998). 
IP3 binds to its receptor in the membrane of the endoplasmic reticulum and induces 
the release of intracellular calcium, whereas DAG associates with certain isoforms 
of the serine/threonine protein kinase C (PKC), promoting their activation (Berridge, 
Bootman et al. 1998). The nvinduced emptying of intracellular calcium stores 
triggers the entry of extracellular calcium through store-operated calcium channels 
in the plasma membrane and degranulation (Hoth and Penner 1992; Scharenberg and 
Kinet 1998).
Degranulation is strictly dependent on the influx of extracellular calcium. Indeed, 
EGTA chelation of extracellular calcium results in the complete abrogation of 
antigen-induced mast cell exocytosis (Huber, Helgason et al. 1998). Optimal 
degranulation also requires inputs other than calcium entry, which is a crucial 
trigger, but not the only factor responsible for degranulation (Ludowyke, Scurr et al. 
1996). The calcium ionophore A23187, can trigger degranulation of mast cells, but 
less than that elicited by IgE/antigen crosslinking. However, IgE/antigen-triggered 
degranulation can be mimicked by A23187 in combination with the potent PKC
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activator, phorbol ester Phorbol-12-myristate-13-acetate (PMA) (which fails to 
trigger degranulation in isolation), which suggests that other signals including PKC 
activation have to be generated for optimal degranulation (Ludowyke, Scurr et al. 
1996).
1.8.2 Pharmacological or antibody neutralisation o f  PI(3)K activity 
attenuates mast cell exocytosis
1.8.2.1 PI(3)K inhibitors attenuate mast cell exocytosis 
Broad spectrum PI(3)K inhibition by LY294002 or wortmannin leads to a profound 
attenuation of mast cell exocytosis (Yano, Agatsuma et al. 1995; Marquardt, Alongi 
et al. 1996). Inhibition of calcium flux appears to be partly the mechanism by which 
wortmannin inhibits degranulation. Wortmannin-treated RBL2H3 cells (a rat mast 
cell line) have a reduced amplitude and duration of the sustained phase of the 
calcium response. PI(3)K activation may also be downstream of calcium 
mobilisation (Huber, Hughes et al. 2000). Thapsigargin is tumor promoter which can 
induce mast cell degranulation by draining of calcium ions from the endoplasmic 
reticulum leading to capacitative entry of extracellular calcium through store- 
operated calcium surface channels, and subsequent degranulation (Bird and Putney 
1993; Thastrup, Dawson et al. 1994).
Thapsigargin acts by inhibiting the sacrcoplasmic/endoplasmic reticulum calcium- 
dependent ATPase, which pumps calcium that leaks from the endoplasmic reticulum 
back into this organelle (Bird and Putney 1993). Thapsigargin-stimulated 
degranulation is PI(3)K-dependent and treatment of BMMCs with thapsigargin
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transiently activates PI(3)K-dependent PKB (Huber, Hughes et al. 2000). However 
unlike A23187 and IgE/antigen-induced calcium mobilisation, thapsigargin- 
stimulated calcium mobilisation is insensitive to PI(3)K inhibitors (Marquardt, 
Alongi et al. 1996; Huber, Hughes et al. 2000). Thapsigargin-stimulated calcium 
release is thought to activate PI(3)K which together with PKC can augment the 
degranulation response.
1.8.2.2 Neutralisation o f  class IA catalytic subunits attenuates 
exocytosis
Studies in which neutralising antibodies to class IA subunits have been 
microinjected into RBL2H3 cells, indicate that all class IA catalytic subunits may 
participate in exocytosis and are involved in driving both calcium-dependent and - 
independent pathways (Ching, Hsu et al. 2001; Smith, Surviladze et al. 2001; 
Windmiller and Backer 2003). However, some functional differences were found 
between p i 10a on the one hand, and pi 10(3 and pi 105 on the other.
Antibody neutralisation of p i 1 Op and pi 105 led to a reduction in the sustained phase 
of the calcium response, indicating that these isoforms mediate the wortmannin- 
sensitive steps in calcium signalling (Smith, Surviladze et al. 2001).
Neutralisation of p i 10a has no affect on calcium signalling but can still 
substantially diminish mast cell exocytosis (Windmiller and Backer 2003). The 
mechanism by which p i 10a PI(3)K activity contributes to exocytosis is unclear. 
There is also evidence to suggest that p i 10p maybe important in adenosine- 
potentiated degranulation at suboptimal concentrations of antigen. Neutralisation of
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pi 10p but not p i 108 or p i 10a was found to lead to a substantial attenuation of 
adenosine-potentiated mast cell degranulation (Windmiller and Backer 2003). The 
mechanism by which pi 10p can contribute to this type of response remains 
unknown.
1.8.3 PI(3)K associates with two parallel pathways activated 
downstream o f FceRI
There is now a general consensus regarding the signalling pathways downstream of 
FcsRI. Two parallel pathways are activated following antigen aggregation of FceRI 
receptors, namely the Lyn-Syk-LAT and the Fyn-Gab2-PI(3)K axes (Fig 1.9). 
Electron microscopy suggests that PI(3)K associates with both pathways which are 
located within different intracellular compartments (Wilson, Pfeiffer et al. 2002). 
Gene-targeted disruption of the adaptor proteins (LAT or Gab2) which form the 
nucleus of these pathways leads to profound attenuation of mast cell degranulation 
and the in vivo allergic response. Overall it seems that the Lyn-Syk-LAT and the 
Fyn-Gab2-PI(3)K pathways have different functions but complement at the level of 
calcium mobilisation and PKC activation.
1.8.3.1 The Fyn-Gab2-PI(3)K pathway
Antigen aggregation of FcsRI leads to association of the PTK Fyn with the FcsRIp 
chain. Fyn phosphorylates Gab2 which then associates with a number of molecules 
including SHP-2 and PI(3)K. Gab2 null BMMC have an 80% reduction in class IA 
PI(3)K activity and a substantial attenuation of PKB phosphorylation stimulated by
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IgE/antigen. The severe reduction in PI(3)K activity is thought to account for the 
-65% reduction in BMMC degranulation in vitro and the attenuated in vivo 
IgE/antigen-dependent allergic response. The exact contribution of Gab2/PI(3)K 
recruited to FcsRI-complexes upon IgE/antigen stimulation is not clear (Rivera, 
Cordero et al. 2002; Fukao, Terauchi et al. 2003; Blank and Rivera 2004). Apart 
from the reduced PI(3)K activity IgE/antigen-stimulated Gab2 null BMMC also 
have a reduction in PLCyl tyrosine phosphorylation and a partially reduced calcium 
flux, although there is some data to suggest that PI(3)K can enhance PLCy activity 
(discussed in section 1.8.6) it is not clear whether this reduction in PLCyl 
phosphorylation in Gab2 null cells is a consequence of the reduction in PI(3)K 
activation or loss of Gab2/PLCyl protein-protein interactions (Gu, Saito et al. 2001; 
Xie, Ambudkar et al. 2002).
It has been suggested that Gab2 associated PI(3)K activity may also influence PKC 
activation by way of PDK-1, however without direct PKC and PDK-1 activity data 
this hypothesis requires confirmation. PDK-1 is constitutively active and although it 
possesses a PH domain there is no data to suggest that PI(3)K activity is important 
for recruiting or activating PDK-l(Sonnenburg, Gao et al. 2001). PI(3)K activity is 
more likely to be important for recruiting PDK-1 substrates such as PKB to the 
membrane where they are phosphorylated (Gu, Saito et al. 2001).
Overall it would seem that Gab2/PI(3)K has functions beyond PLCy and PKC 
activation. There are a large number of PI(3)K targets including Tec family protein
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tyrosine kinases (such as BTK), GDP-GTP exchange factors (such as P-Rex-1 and 
cytohesins) and GTPase-activating proteins (including those that activate Arf, 
centaurin-a or Ras, GAPlm, G aplIP4BP) some of which may have a role in secretory 
granule exocytosis(Vanhaesebroeck, Leevers et al. 2001).
1.8.3.2 The Lyn-Syk-LAT pathway
IgE/antigen-stimulation leads to activation of the constitutively FcsRI associated Src 
family PTK Lyn which phosphorylates tyrosine residues within the FcsRI(3 and 
FcsRIy chains leading to recruitment of additional Lyn and the Syk PTK which 
signals downstream of FcsRIy chain (Kinet 1999; Blank and Rivera 2004). The 
recruitment of Syk is associated with phosphorylation of the LAT adaptor protein 
and the formation of a signalling complex termed a ‘signalosome’ which is primarily 
concerned with calcium mobilisation and PKC activation. LAT associates with a 
large number of molecules including PLCy, adaptor proteins (such as Gads, SLP-76, 
Grb2) GDP-GTP exchange factors (such as Vav) GTPases (Rac) and PI(3)K (Blank 
and Rivera 2004). Deletion of LAT leads to reduced activation of many of these 
signalling proteins and LAT-deficient mast cells have a severe attenuation of 
calcium signalling, degranulation and cytokine release upon IgE/antigen-activation 
(Saitoh, Arudchandran et al. 2000). Many of the signalling proteins which associate 
with LAT augment the activity of PLCy which is the principal driving force behind 
mast cell calcium mobililsation (Blank and Rivera 2004).
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The downstream targets of PI(3)K activity within the Lyn-Syk-LAT pathway are not 
clear. Brutons tyrosine kinase (BTK) has been identified as one of the downstream 
targets of PI(3)K activity which associates with the LAT pathway and can influence 
PLCy activation (Hata, Kawakami et al. 1998). BMMC which lack BTK or have a 
mutation within the BTK PH domain have a partial attenuation of IgE/antigen 
stimulated calcium flux and the degranulation response (Hata, Kawakami et al.
1998). Few other PI(3)K downstream targets have been identified, currently there is 
more data available on proteins which can activate PI(3)K including Vavl and Rac2. 
Genetic deletion of these PI(3)K ‘activating’ molecules often leads to a reduction in 
IgE/antigen-stimulated PI(3)K activity, calcium flux and mast cell degranulation, 
however as many of these proteins also activate a range of other molecular targets it 
is not clear whether the reduction in PI(3)K activity in BMMC derived from these 
mice is directly responsible for the defects in mast cell responses, or whether these 
deletions have also disrupted other molecular interactions which maybe more 
important for mobilising calcium and the exocytosis process. (Pivniouk, Martin et 
al. 1999; Manetz, Gonzalez-Espinosa et al. 2001) (Yang, Kapur et al. 2000).
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Fig 1.9. Pathways to mast cell degranulation downstream of the FcsRI receptor
1.8.4 Class IA PI(3)K regulatory subunits appear to be not required 
for mast cell exocytosis
Gene targeting allows for a more focused study of PI(3)K activation downstream of 
FcsRI. Loss of class IA p85 regulatory subunits through partial or complete 
disruption of PIK3rl or PIK3r2 has no impact on calcium mobilisation, in vitro mast 
cell exocytosis or in vivo anaphylaxis (Table 5) (Lu-Kuo, Fruman et al. 2000; Fukao, 
Terauchi et al. 2003; Tkaczyk, Beaven et al. 2003). In one report IgE/antigen 
stimulated PKB phosphorylation was enhanced (in pan-p85a null mast cells) and in 
another kinetically altered (in p85p null mast cells) suggesting that PI(3)K activity 
was certainly not reduced (Table 5) (Lu-Kuo, Fruman et al. 2000; Tkaczyk, Beaven 
et al. 2003).
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The observed increase in PI(3)K (in the pan-p85a KO mast cells) activity is 
particularly surprising as disruption of the PIK3rl has been shown to lead to a down 
regulation of expression all class IA pi 10 subunits (Lu-Kuo, Fruman et al. 2000). 
Although it is possible that in each of these KO mice the remaining regulatory 
subunit coupled to p i 1 0  isoforms compensate for lack of the targeted subunit and 
maintain normal mast cell degranulation, it is not clear why conditions of reduced 
p i 10 expression would lead to increased PI(3)K activity. A possible mechanism for 
the increase in PI(3)K activity is loss of p85/PTEN phosphatase interactions a 
consequence of p85 targeting. The PTEN phosphatase normally modulates PI(3)K 
activity by removing the 3-phosphate from PIP3 it has been found that loss of p85a 
has a knock-on reduction in PTEN activity in embryonic fibroblasts and remains to 
be investigated in p85 KO BMMC (Ueki, Fruman et al. 2002). It is possible that 
selection for immortalized p85a KO MEFs has selected for cells lacking PTEN. It is 
also possible that the compensating PI(3)K activity may not be class LA PI(3)K- 
mediated but by other classes of PI(3)K.
1.8.5 p llO y  is critical for mast cell activation and the allergic immune 
response
Recent data suggest that p i lOy plays an important role in mast cell activation, p i lOy 
is recruited by the adaptors p i01 and p84 to GPCR signalling and participates 
indirectly with FcsRI signalling by way of an autocrine or paracrine loop 
mechanism. Initial activation of FcsRI leads to liberation of intracellular GPCR
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agonists like adenosine, which upon interaction with their cognate receptors on the 
mast cell surface activate pi lOy. Activation of p i lOy by this route provides an 
apparently critical burst of PI(3)K activity which overcomes the negative elements 
of PI(3)K signalling (SHIP and PTEN) leading to full degranulation. Loss of p i lOy 
leads to a reduction in mast cell responsiveness to GPCR ligands and a reduced in 
vitro degranulation without affecting IgE/antigen activated calcium mobilisation 
(Laffargue, Calvez et al. 2002; Wymann, Zvelebil et al. 2003; Wymann and Marone 
2005). However these in vitro mast cell exocytosis defects appear to be dose- 
dependent. No defects are apparent at low antigen concentrations and the autocrine 
loop can be overcome with higher concentrations of adenosine. Additionally, p i lOy- 
deficient BMMCs activated with IgE/antigen remain sensitive to PI(3)K inhibitors 
which suggests that other PI(3)Ks may be involved in this process. Irrespective of 
these in vitro findings, in vivo the autocrine loop and pi lOy activity appear critical 
for IgE/antigen-dependent anaphylaxis to which pi lOy-deficient mice are resistant 
(Laffargue, Calvez et al. 2002).
1.8.6 Contribution ofPI(3)K isoforms downstream o f FcsRI remains 
controversial
Genetic studies have identified a large number of PI(3)K interacting proteins 
downstream of IgE/antigen stimulated FcsRI-complexes, these include adaptor 
proteins (Gab2), GEFs (Vavl), GTPases (Rac2), Src and Tec family PTK (Fyn and 
Btk respectively) etc, however most of molecules apart from BTK have been found 
to be upstream or parallel to PI(3)K activation. Thus a critical ?l(3)K-dependent
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molecule, which when inactivated/deleted would lead to attenuation o f degranulation 
response similar to that observed upon wortmannin treatment of BMMC, has not yet 
been identified downstream of FceRI.
BMMC exocytosis is profoundly inhibited by wortmannin, the degranulation event 
most sensitive to this inhibitor is calcium flux. To date research has been focused on 
trying to establish how PI(3)Kcan activate the molecules involved in IgE/antigen- 
dependent calcium flux. PLCy contains a PH domain and is essential for calcium 
mobilisation, there are data to suggest that PI(3 )K/PIP3 can directly activate/increase 
its enzymatic activity through allosteric mechanisms. There is also data which 
indicates that PI(3)K can augment the activity of PLCy which is already tyrosine 
phosphorylated (Falasca, Logan et al. 1998; Smith, Surviladze et al. 2001). However 
direct PLCy activation by PI(3)K is disputed by a more recent study in which it was 
found that wortmannin pre-treatment of primary human and mouse mast cells 
(which completely abrogated PKB phosphorylation) failed to inhibit PLCy activation 
and the initial phase of the IgE/antigen-stimulated calcium response (Tkaczyk, 
Beaven et al. 2003). This PLCy dependent and PI(3)K independent phase of the 
degranulation response was found to be able to maintain a basal level of wortmannin 
insensitive IgE/antigen-stimulated mast cell degranulation (20% in mouse mast cells 
and 50% in human mast cells) (Tkaczyk, Beaven et al. 2003). This study also 
showed that the latent phase of calcium response is wortmannin sensitive and is 
necessary for optimal degranulation(Tkaczyk, Beaven et al. 2003). The latent phase 
of calcium flux correlates with influx of calcium from the extracellular environment,
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there is data to suggest that PIP3 can directly or indirectly via Tec family PTK (such 
as BTK) activate plasma membrane channels which control calcium influx (Ching, 
Hsu et al. 2001).
To date most research has focused on the role of PI(3)K in calcium mobilisation 
despite evidence that PI(3)K may also have other roles. Gab2 null BMMC which 
have a substantial reduction in IgE/antigen stimulated degranulation do not have a 
severe attenuation of calcium mobilisation. Furthermore pi 10a neutralising 
antibodies which do not attenuate calcium mobilisation can also reduce mast cell 
exocytosis. These data are indicative that PI(3)K may also have other molecular 
targets involved in the exocytosis process (some of these are highlighted in section 
1.8.3.1)
In summary, although PI(3)K activity appears essential for mast cell activation, the 
nature of the PI(3)K(s) involved remains controversial. Genetic models lacking class 
IA regulatory subunits preclude a major role for this family in driving IgE/antigen 
dependent exocytosis. However incomplete disruption of these regulatory adaptor 
proteins leaves the possibility of compensation by the remaining adaptor proteins. 
The involvement of class IA PI(3)K activity is supported by genetic data obtained 
from the Gab2 KO mouse, which forms a major PI(3)K adaptor protein with 
multiple YxxM motifs able to bind the p85 subunit and is central to one o f two 
parallel pathways critical for mast cell degranulation (see section 1.8.3). Gab2null 
BMMCs have a severe reduction in PI(3)K activity (as assessed by both direct and
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indirect means) which correlates with a substantial defect in in vitro exocytosis and 
cytokine production.Gab2 null mice are less sensitive to IgE/antigen-dependent 
systemic anaphylaxis.
It is also possible that non-class IA PI(3)K may also contribute towards mast cell 
degranulation and there is genetic data to indicate that the p i lOy PI(3)K can 
contribute by way of an autocrine loop mechanism which is essential for optimal 
mast cell degranualation.
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Table 1.5 Role of PI(3)K in mast cell activation.
FceRI (Triggered by IgE/antigen cross-linking) In vivo (IgE/Ag)
Targeted
subunit
PI3K
activity
PI3K
activity
Degranulation Cytokine
release
Calcium
Flux
Cutaneous
anaphylaxis
Systemic
anaphylaxis
Reference
p85a,
p50a,
p55a
pan - 
p85associated
t  pAkt OK
(Lu-Kuo, Fruman
•I p85P associated
et al. 2000)
p85a - i ’ pAkt OK 4 TNFa (in vivo) - - OK (Fukao, Yamada 
et al. 2002), 
(Tkaczyk, Beaven 
et al. 2003)p85p -
t  pAkt (Early 
phase) OK - - - -
pllOSKI
U  YxxM 
phosphopeptide
^ p A k t I
-1 TNFa
i (Ali, Bilancio et
W  pi 108 associated llL -6
al. 2004)
pllOy I  PIP3 : GPCR
t  pAkt i : IgE/Ag OK:
IgE/Ag W :
1 1
(Laffargue,
stimulated I'^pAkt: IgE/Ag + 
Adenosine
: adenosine + 
IgE/Ag
■I: IgE/Ag 
+ adenosine
Adenosine
alone
Calvez et al. 
2002)
-: Not reported 
OK : Measured but not affected 
I : Partial reduction 
i i  : Substantially reduced / Abrogated
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Introduction
Aims and objectives
Many of the fundamental biological responses which are thought to maintain mast 
cell homeostasis are PI(3)K-dependent, as evidenced by the inhibitory effect of 
broad spectrum PI(3)K inhibitors which block all 8  members of the extended PI(3)K 
family. The class IA subset of PI(3)Ks which operates in the context of tyrosine 
kinase signalling, is thought to drive a significant number of responses accredited to 
PI(3)K activity. This includes growth factor-dependent proliferation, survival and 
IgE/antigen-dependent secretory granule exocytosis, responses known to be driven 
to a large extent by tyrosine kinase signalling. At the start of this work, there were 
few genetic data which could confirm these claims. Indeed, many of the published 
reports regarding the role of class IA PI(3)Ks in mast cell biology are from studies 
which have either used indirect targeting strategies, removing important PI(3)K 
scaffolding proteins such as Gab2 or have introduced genetic mutations which 
prevent specific receptor from associating with PI(3)K, such as in the 
KitY7 1 9F/KitY719F mice. The interpretation of results from these approaches can be 
complicated by ‘knock-on’ effects which are a consequence of the loss of protein- 
protein interactions unrelated to PI(3)K. In addition, mast cells from mice in which 
members of the class IA regulatory subunit family have been removed has in many 
cases failed to provide phenotypes consistent with a key positive role of PI(3)K in 
mast cell biology and function. In fact, in some instances an even evidence of 
increased PI(3)K activity was observed in the absence of regulatory adaptors.
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This study therefore aimed to more clearly delineate the role of specific class I 
PI(3)K catalytic isoforms in mast cell biology. Using a combination of gene 
targeting and pharmacological approaches, we aimed to assess the contribution of 
the kinase activity (independently of any scaffolding functions) of p i 106, a PI(3)K 
isoform which is mainly expressed in leukocytes. Our objectives are (1) reassess the 
role of class IA ¥\(2>)-kinase activity in mast cell responses including growth factor 
responses which can influence mast cell homeostasis and its role within the allergic 
immune response (2 ) assess any p i 106-iso form specific functions.
Chapter 2 Methods
2. Materials and Methods
2.1 M ice
p i io§D910A/D910A mice have been described previously (Okkenhaug, Bilancio et al. 
2002) and were backcrossed on a C57BL/6 or Balb/c background for 6-10 
generations. Age-matched, 6-10 week old littermate mice were used for all 
experiments.
2.2 In vitro methods
2.2.1 A n tib o d ie s  a n d  p h a rm a c o lo g ic a l in h ib ito rs
Stock solutions of small molecule inhibitors were prepared to a final concentration 
of 10 mM in dimethylsulfoxide (DMSO) (Sigma) from powdered stocks. In cell- 
based studies, inhibitors were added 20 min prior to stimulation. In all experiments 
where pharmacological inhibitors were used, an equivalent volume of DMSO 
vehicle was used in the control samples.
Commercial sources of antibodies and inhibitors used were as follows: p-Akt/PKB 
S473, Akt/PKB and , p-JNK Thrl83, Thrl85 were purchased from Cell Signalling 
Technology (Beverly, MA); Kit-receptor (C-14), p i 10p, p i 105, p-ERK Y204 (E-4), 
Erk were from Santa Cruz Biotechnology (Santa Cruz, CA); p-actin was purchased 
from Sigma; LY294002 was purchased from Calbiochem.
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2.2.2 M a s t cell c u ltu re s
Total bone marrow samples from the femurs of 3-5 mice were cultured in RPMI 
1640 medium supplemented with 10% ultra-low IgG FBS (GIBCO), 10 ng/ml IL-3 
(Tebu-bio), 20 ng/ml SCF (Tebu-bio), 2 mM L-glutamine, 100 units/ml penicillin 
and streptomycin (GIBCO) in a 5% CO2 atmosphere. Bone marrow progenitors 
were obtained by flushing isolated femurs with a 2  5-gauge needle and 2  ml of 
culture medium without growth factors. Cells were counted and seeded at a 0.5x106 
cells/ml. The following day the non-adherent cells were removed and transferred to 
a new tissue culture flask. Cultures were refed with fresh media and IL-3 and SCF 
every 2  days for the first 2  weeks and then once a week for the remaining culture 
period.
BMMCs were harvested after an at least 4 week maturation period and tested for Kit 
receptor and FcsRI expression by flow cytometry using phycoerythrin-labelled rat 
anti-Kit (CD117; Pharmingen) or anti-DNP IgE (SPE-7; Molecular Probes) and 
monoclonal FITC-anti-mouse IgE (Molecular Probes), respectively. BMMCs used 
for this study were cultured in IL-3 and SCF, unless otherwise indicated, with 
culture times not exceeding 6  weeks.
2.2.3 C y to k in e  s tim u la tio n , lysis a n d  im m u n o b lo ttin g
2.2.3.1 Cytokine stimulation and lysis
Cells were starved for 24 h in normal culture medium lacking IL-3 and SCF. 
Following stimulation (at 37°C), the cells were washed twice with ice-cold PBS, and
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whole-cell lysates were prepared by lysis of pellets in ice-cold lysis buffer (50 mM 
Tris-HCl (pH 7.4), 1% (w/v) Triton X-100, 150 mM NaCl, 1 mM Ethylenediamine 
tetra-acetic acid (EDTA), 1 mM NaF, 1 mM Na3V0 4 , 1 mM phenylmethylsulfonyl 
fluoride, 0.09 trypsin inhibitor units/ml aprotinin (Sigma), 10 pM leupeptin (Sigma), 
0.7 pg/ml pepstatin A (Sigma), 27 mM sodium p-tosyl-L-lysine chloromethyl ketone 
(Sigma) and 1 mM DTT) for 15 min after which insoluble fractions were removed 
by centrifugation (4°C) at 14,000 rpm for 15 min. Protein concentration (Bio-Rad 
protein assay) of the supernatant was determined, followed by addition of sample 
buffer (5x concentrated: 25% glycerol (v/v), 5% SDS (w/v), 250 mM DTT, 156.25 
mM Tris.HCl, pH 6 .8 ) and heating to 100°C for 5 min.
2.23 .2  Immunoblotting
Proteins were resolved on 8 % polyacrylamide-SDS gels (constant voltage, 60V 
overnight) and transferred onto Immobilon-P polyvinylidene fluoride (PVDF) 
membranes by wet transfer (200 mA, 6  h) (Millipore). Following transfer, 
membranes were incubated in blocking buffer (5% (w/v)) dried skimmed milk in 
0.1% (v/v) Tween 20 in phosphate buffered saline (PBS-T) for 1 h at room 
temperature to saturate the aspecific protein binding sites on the membrane.
For immunoblotting, primary antibodies were prepared in PBS-T containing 0.02% 
azide (w/v) (for phosphospecific antibodies, bovine serum albumin (BSA) and Tris- 
buffered saline were used). Membranes were incubated with primary antibodies at 
room temperature overnight on a rocking platform following which membranes were
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washed three times (5 min) with PBS-T. Secondary antibodies, conjugated to 
horseradish peroxidase (HRP) were diluted 1:5000 in 10 ml of 1% milk in PBS-T 
and incubated with membranes for 1 h at room temperature. The membrane was 
then washed three times (5 min) in PBS-T and bound antibody was detected with 
enhanced chemiluminescence reagent (Amersham Pharmacia).
2.2.4 L ip id  k in a se  assay
2.2.4.1 In vitro PI(3)K lipid kinase assay
In vitro lipid kinase assays were carried out on exponentially growing BMMCs.
Cells were washed two times with ice-cold PBS and lysed at 4°C in lysis buffer for 
30 min (see section 2 .2 .2 ) after which insoluble fractions were removed by 
centrifugation (4°C) at 14,000 rpm for 15 min. Following determination o f protein 
concentration, immunoprecipitations were performed on 500 pg total cell lysate 
using PI3K isoform-specific antibodies for 1 h at 4°C under rotation. After 
incubation, immune complexes were captured on protein A-sepharose beads (20 pi 
of 1:2 slurry) by incubation for a further 2 h. Precipitates were washed three times 
with PI(3)K kinase buffer (40 mM Tris.HCl pH 7.4, 200 mM NaCl, 1 mM EGTA) 
before kinase assays were carried by addition of ATP and Mg2+ (1 mM ATP, 2.7 
mM MgCE and 0.23 pCi of [y-3 2P]ATP/assay (Amersham)) using 200 pg/ml 
phosphatidylinositol(4,5)bisphosphate (sonicated for 15 min before use) as a 
substrate. Kinase reactions were performed in a final volume of 60 pi for 15 min at 
37°C after which the reaction was quenched by adding 100 pi 0.1 M HC1, followed 
by 200 pi of chloroformimethanol (1:1). The mixture was vortexed and the phases
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were separated by centrifugation at 13,000 rpm for 2 min. The aqueous phase was 
discarded and the lower organic phase was washed with 200 pi 1 M HChmethanol 
( 1 :1 ), by centrifugation (13,000 rpm, 2  min) and the aqueous phase was again 
discarded. The lower organic phase was spotted onto thin layer Silica Gel-60A 
plates (Whatman), pretreated with 1% oxalic acid, 1 mM EDTA, 40% methanol. 
TLC plates were run in propan-l-ol, 2 M acetic acid, 5 M H3PO4 . (65:35:1). After 
the TLC run, the plates were allowed to dry and autoradiographed. Images of the 
radiolabelled lipid products were acquired with a Phosphorlmager (BioRad) and 
signals expressed as arbitrary units. The activity within control IgG 
immunoprecipitates was subtracted from each immunoprecipitate.
2.2.4.2 Determination o f  total class IA PI(3)K lipid kinase activity 
To assess the total class LA-associated PI3K activity in vitro, cell extracts were 
absorbed on a phosphotyrosine peptide matrix and lipid kinase activity was 
determined (as described in paragraph 2.2.3.1). The YpVPMLG [Yp = 
phosphotyrosine] peptide matrix used is based on the class IA PI3K docking sites in 
the intracellular part of the tyrosine-phosphorylated PDGF receptor and contains the 
consensus binding motif for the SH2 domains of the regulatory subunits of the class 
LA PI3Ks.
2.2.4.3 Determination o f  in vivo PIP3 levels
In vivo levels of PIP3 were determined by a time-resolved fluorescence resonance 
energy transfer ligand displacement assay, as described (Gray, Olsson et al. 2003).
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BMMCs were starved overnight culture media without growth factors, stimulated 
the next day in the same media with 100 ng/ml SCF for 10 min and centrifuged at 
4°C, 1200 rpm for 5 min after which pellets were resuspended in 0.5 M TCA and 
immediately frozen on dry ice.
2.2 .5  D N A  sy n th esis  a n d  m a s t cell ex p an s io n
Following a 24 h starvation in culture medium without IL-3 and SCF, 105 cells in 
triplicate were incubated in 96-well plates (Costar) with 20 ng/ml IL-3 and/or 20 
ng/ml SCF, together with 0.5pCi [3H]-Thymidine (Amersham) and harvested 24-72 
h later onto a solid filter using a cell harvester (Perkin Elmer), and counted, 
following application of scintillate using a 96 well Perkin-Elmer Microbeter counter. 
For expansion assays BMMC were starved overnight in culture medium without IL- 
3 and SCF, cells were seeded at 0.5x106 cells/ml in 5 ml medium with 20 ng/ml IL-3 
or 20 ng/ml IL-3 and SCF. Viable cell numbers were determined every 24 h for a 96 
h period using a Casey counter.
2 .2.6 D e g ra n u la tio n  a n d  c y to k in e  sec re tio n
Mast cells were washed and re-suspended in Tyrodes buffer (10 mM HEPES, 130 
mM NaCl, 6.2 mM D-glucose, 3.0 mM KC1, 1.4 mM CaCb, 1.0 mM MgCh and 
0.1% BSA). Unless otherwise stated, cells (5.104 /well) were plated in triplicate in 
96-well flat bottom plates and stimulated for 60 min with IgE/antigen complex [100 
ng/ml anti-DNP IgE and 200 ng/ml DNP/HSA (Sigma)] in a final volume of 110 pi, 
followed by harvesting of cell supernatant and cell pellets. In some experiments,
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cells were sensitized overnight with 1 pg/ml anti-DNP IgE, followed by extensive 
washes and incubation with DNP/HSA, and further treated as above. Cytokine 
released into the supernatants was assessed using Quantikine kits (R&D Systems). 
For measurement of (3-hexosaminidase activity, 50 pi of supernatant or lysed cell 
pellet [lysed in 110 pi using hexadecyltrimethyl-ammonium bromide (HTAB; 
Sigma)] were incubated with 50 pi 3.7 mM p-nitrophenol-N-acetyl-p-D- 
glucosaminide for 1 h, followed by quenching of the enzymatic reaction by addition 
of 100 pi 2 M NaOH and measurement absorbance at 405 nm. Degranulation is 
expressed as a percentage of total p-hexosaminidase activity in the input cells.
2 .2 .7  H u m a n  m a s t cell s tu d ie s
Human mast cells were obtained by culture of peripheral blood CD34+ cells in Stem 
Pro 34 media (Invitrogen, Calsbad, CA, USA) containing recombinant human IL-3 
(30 ng/ml), IL- 6  (100 ng/ml) and SCF (100 ng/ml) (Pepro Tech, Rocky Hill, NJ, 
USA) for 1 week, followed by culture without IL-3 (but with IL- 6  and SCF as 
above) for a further 6-7 weeks as described(Okayama, Tkaczyk et al. 2003). For 
degranulation studies, cells were starved of cytokines overnight and sensitized with 
myeloma-derived human IgE (Calbiochem) which was biotinylated. Following 
rinsing with HEPES buffer (as described in (Okayama, Tkaczyk et al. 2003)) 
containing 0.04% BSA (Sigma) the cells were plated into 96-well tissue culture 
plates at 1 0 , 0 0 0  cells per well (with or without inhibitors) and incubated for 15 min 
at 37°C. Following addition of antigen and/or SCF, degranulation was allowed to 
proceed for 30 min. The reaction was terminated by centrifugation (4°C, lOOOx g, 5
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min) and aliquots removed for p-hexosaminidase assay. The remaining cells were 
lysed by freeze-thawing and duplicate aliquots of these fractions assayed for p- 
hexosaminidase content. Release was subsequently calculated as the % of total 
(lysate + supernatant) p-hexosaminidase present in the supernatant.
2.2 .8  C ell a d h es io n  a n d  m ig ra tio n
For adhesion assays, cells starved of cytokines for 24 h were washed and 
resuspended in culture medium without cytokines. Cells were plated at 5.104/well in 
a 50 pi volume in 96-well plates (Costar) pre-coated overnight with 5 pg/ml human 
plasma fibronectin (Gibco). Following 30 min stimulation with or without SCF (in 
1 0 0  pi final volume), non-adherent cells were removed by inverting plates for 15 
min. The adherent cells were lysed using hexadecyltri ammonium bromide 
(HTAB) and p-hexosaminidase activity measured to assess the fraction of adherent 
cells. Adhesion is expressed as percentage of input. For migration assays, 
exponentially growing cells were washed and resuspended in Tyrodes buffer. 105 
cells were seeded in 1 0 0  pi in the upper chamber of 8  pm pore diameter transwells 
(BD Biosciences) with or without 100 ng/ml SCF in Tyrodes buffer in the lower 
chamber. After a 3-4 h incubation at 37°C and 5% CO2 , the cells in the lower 
chamber were lysed using HTAB and P-hexosaminidase activity measured to assess 
the fraction of migrated cells.
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2 .2.9 C a lc iu m  flux
Calcium flux was measured in exponentially growing BMMCs. Cells were re­
suspended in Hanks-buffered saline solution containing Ca2+, Mg2+ (no additional 
Ca2+ or Mg2+ was added)(HBSS, Gibco), 2.5 mM probenicid (Sigma) (to prevent 
dye exclusion) and pre-incubated with 1 pM Fluo-4 (Molecular Probes) for 20 min 
at 37°C after which 100 pM brilliant black (ICN Biochemicals) was added (to permit 
fluorescence visualisation) 100 pi (4xl05 cells/well) of cell the solution was plated 
in quadruplicate into 96-well plates (NUNC) and centrifuged at 1300 rpm for 5 min. 
Stimulations and fluorescence measurements were carried out using an automated 
FLIPRI machine (Molecular Devices). BMMC were stimulated with 50 pi of 3x 
concentrated stimulus and the calcium response was followed (over 500 sec.) by 
measuring fluorescence emission (excitation 488 nm and emission 520 nm). Results 
are expressed as normalised fluorescence change over time.
2.3 In vivo experiments
2.3.1 P assive  c u tan e o u s  a n ap h y la x is
The PCA protocols were adapted from Ref. (Tilley, Wagoner et al. 2000). For PCA 
in the back skin, mice were lightly anaesthetised and injected intradermally at two 
dorsal sites with 100 ng of murine monoclonal anti-DNP IgE in 20 pi of saline. 24 h 
later, the mice were injected intravenously with 100 pg of DNP-albumin in 100 pi 
0.5% Evan’s blue dye in saline (added to permit visual localization of increased 
vascular permeability). Control mice were given dye in saline only. After 30 min,
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animals were terminally anaesthetized, and biopsies around injection sites taken. 
Evan’s blue dye was extracted by incubation of biopsies in 1 ml formamide at 55°C 
for 48 h and the anaphylactic reaction quantified by measuring the absorbance of at 
620 nm (A620). For PCA in the ear, mice were sensitized in one ear with 50 ng 
anti-DNP IgE diluted in 20 pi saline and were given a sham saline injection in the 
other ear. 24 h later, the mice were injected intravenously with 1 mg of DNP- 
albumin in 100 pi 0.5% Evan’s blue dye in saline. Ear punches were taken with a 
sample corer (5mm, Fine Science tools) and the PCA response was quantified by 
dye extraction from IgE- and saline-injected ears (as above, but in a 200pl volume). 
Data are expressed as A620 = A620 of IgE-sensitized ear -  A620 of saline-injected 
ear. IC87114 or 75% PEG200 vehicle was administered per os 2 h prior to antigen 
challenge. IC87114 plasma concentration was determined using LC-MS/MS.
2.3.2 P assiv e  system ic  a n a p h y la x is
Mice were sensitized overnight with 2 pg of monoclonal anti-DNP IgE in 200 pi 
saline by tail vein injection 24 h later, the mice were terminally anesthetised by 
intra-peritoneal injection with sodium pentobaribital, 150 mg/kg (Merial) and then 
injected intravenously with 500 pg of DNP-albumin in 100 pi in saline or saline 
alone. The experiment was terminated 2 min after challenge and blood samples were 
taken by cardiac puncture. The PSA response was quantified by measuring serum 
histamine levels using a competitive histamine immunoassay kit (IBL, Hamburg, 
Germany).
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2.4 S ta tis tic a l an a ly s is
All in vitro data shown are representative experiments (mean ± S.D.) from different 
BMMC cultures (established from at least littermate 3-5 mice each). Data for in 
vitro experiments were statistically analyzed using a t-test and differences between 
WT and pi io§D910A/D910A BMMCs were statistically significant (p<0.05) unless 
otherwise stated. Results from in vivo experiments (mean ± S.E.M) were assessed 
using a Mann-Whitney test with results of analysis and animal numbers presented in 
the relevant figure legends. Graphpad Prism software was used for all statistical 
analysis.
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3.0 Role of pi 108 in mast cell homeostasis
3.1 Summary
Previously published work had shown that class IA PI(3)K activity downstream of 
the Kit receptor plays a role in maintaining the homeostasis of (a) subset(s) o f mast 
cells, namely the mast cells within the peritoneum and gastrointestinal tract (Kissel, 
Timokhina et al. 2000; Fukao, Yamada et al. 2002). This most likely relates to the 
observation that Kit-associated PI(3)K activity is important for SCF-induced mast 
cell proliferation and survival (Kissel, Timokhina et al. 2000; Lu-Kuo, Fruman et al. 
2000; Fukao, Yamada et al. 2002).
Using a previously described gene-targeted mouse model (Okkenhaug, Bilancio et 
al. 2002) and a p i 108-selective inhibitor (Sadhu, Dick et al. 2003), we determined 
the role of the class IA PI3K isoform p i 108 in mast cell homeostasis. We found that 
genetic inactivation of p i 108 led to a severe reduction in total cell class IA PI(3)K 
activity and identified pi 108 as the predominant class IA PI(3)K in mast cells.
We found that p i 108D910AD910A bone marrow progenitors supplemented with 
recombinant IL-3 gave rise to substantially reduced numbers (up to 50%) of 
BMMCs. Indeed, genetic or pharmacological inhibition of pi 108 led to a partial 
reduction in IL-3- induced mast cell proliferation and expansion, p 110SD910A/D910A 
BMMC expansion remained LY294002-sensitive and analysis of PI(3)K signalling 
pathways confirmed that other PI(3)K(s) can contribute and provide sufficient input 
to maintain IL-3-induced in vitro mast cell homeostasis. The nature of the p i 108
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independent PI(3)K input and how it couples to the IL-3 receptor remains to be 
established.
SCF/Kit interactions are critical for in vivo mast cell homeostasis. Mast cells express 
all class IA PI(3)K subunits but have a critical need for p i 108 activity which has an 
exclusive role downstream of the Kit receptor. Genetic or pharmacological blockade 
of p i 108 activity severely attenuated SCF-induced responses such as proliferation, 
adhesion and migration.
The in vivo consequences of these growth factor defects in p i 108 mutant mice are 
similar to those seen in mice lacking p85a and in mice with a mutation within the 
Kit receptor which can no longer interact with PI(3)K, namely a tissue site-selective 
reduction in mast cell populations.
We conclude that mast cell homeostasis is maintained by PI(3)K pathways both 
dependent and independent of p i 108. Whereas the Kit receptor appears to be 
particularly sensitive to p i 108 inhibition, other cytokine receptors are able to utilise 
non-pl 108 sources of PI(3)K together with PI(3)K-independent pathways (such as 
the Extracellular-Signal Regulated Kinase (ERK) pathway) to maintain in vivo mast 
cell homeostasis. Our data suggest a differential coupling of growth factor receptors 
to PI(3)K isoforms. Indeed, whereas the IL-3 receptor appears to be able to couple to 
one or more PI(3)K isoforms, the Kit receptor exclusively utilises p i 108 to drive 
PI(3)K-dependent responses.
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3.2.1Role o f  p i  108in mast cell growth and differentiation
Mast cell homeostasis is dependent on SCF/Kit interactions and is also under the 
influence of Th2 cytokines (such as IL-3) derived from the local tissue environment 
(Metcalfe, Baram et al. 1997). In vitro mast cells can be derived from bone marrow 
progenitors supplemented with growth factors such as IL-3 and SCF.
Broad-spectrum PI(3)K inhibition has been reported to lead to profound attenuation 
of IL-3- and SCF-induced proliferation of mast cells (Scheid, Lauener et al. 1995; 
Scheid and Duronio 1998; Lu-Kuo, Fruman et al. 2000; Fox, Crew et al. 2005). 
When we initiated this work, genetic evidence from mouse gene targeting precluded 
a role for the class IA PI(3)K system in IL-3-driven mast cell development (Lu-Kuo, 
Fruman et al. 2000; Fukao, Yamada et al. 2002). Indeed, bone marrow progenitors 
from class IA regulatory KO mice, cultured in the presence of IL-3, had been 
reported to give rise to similar numbers of BMMCs as wild-type cells, with no 
apparent abnormalities in differentiation (Lu-Kuo, Fruman et al. 2000; Fukao, 
Yamada et al. 2002).
Using a similar culture protocol as used in these PI(3)K KO studies, we set out to 
derive BMMCs from bone marrow progenitors from p i 10SD910A/D910A mice. We 
found that p i 106D910AD910A progenitors gave rise to substantially reduced numbers 
(up to 50% less) of BMMC following a 4-6 week maturation period (Fig 3.1a). We 
found that WT and pi 105D910A/D910A BMMCs expressed similar levels of the high 
affinity receptor for IgE (FcsRI) and the Kit receptor (Fig 3.1b). Furthermore,
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morphological appearance of toluidine blue-stained cells was similar in BMMCs 
from both genotypes (Fig 3.1c).
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Fig 3.1 p i 108 activity is important for in vitro growth but not differentiation a,
Bone marrow progenitor cells were isolated from WT and pllO{P910A/D9WA mice and 
cultured in vitro in the presence o f recombinant IL-3 (20 ng m l1). Following a 4 
week maturation period the number o f viable cells was assessed, (data is average o f  
4 independent cultures containing bone marrow from at least 3 mice), b, BMMCs 
were assessed fo r  mast cell markers. Levels o f Kit and FcsRI expression, c,
Toluidine blue staining o f BMMC from WT andpllO fP910A/D910A mice.
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3.2.2p llO S is the \principal9 class IA PI(3)K in mast cells
pi 105D910A/D910A BMMCs are derived from mice expressing an enzymatically 
inactive form of the pi 105 protein (Okkenhaug, Bilancio et al. 2002). A common 
observation following gene-targeting of Class IA PI(3)Ks is a deregulation of 
expression of the PI(3)K subunit expression (Vanhaesebroeck, Ali et al. 2005). In 
order to assess the impact of p i 105 inactivation, including possible compensation or 
deregulation of the class IA subunits, we assessed several parameters relating to 
PI(3)K expression and activity.
We found that p i 105D910A/D910A BMMCs express inactive p i 105 protein at levels 
similar to those seen in wild-type cells. In addition, expression levels of the other 
class I isoforms (pi 10a, p i 10p, p i lOy and the p85a regulatory subunit) were not 
obviously altered (Fig 3.2a).
Genetic inactivation of p i 105 by point mutation within the ATP binding site leads to 
a complete abrogation of p i 105 lipid kinase activity in lymphocytes (Okkenhaug, 
Bilancio et al. 2002). We confirmed this in pi 105D910A/D910A BMMCs by 
immunoprecipitation (using isoform specific antibodies) of each individual class LA 
catalytic subunits followed by in vitro lipid kinase activity using the physiological 
substrate PIP2 . Indeed, p i 105 activity in p i 105D910A/D910A BMMCs was completely 
abolished with no alterations in the kinase activities of p i 10a and pi 10p (Fig 3.2b). 
We next assessed the relative contribution of pi 105 activity to the overall pool of 
class LA lipid kinase activity in BMMCs. Total BMMC lysates from WT and
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p i io5D910AD910A were incubated with the YpVPMLG peptide (where YP is 
phosphotyrosine) coupled to a sepharose matrix. PI(3)K complexes isolated using 
this matrix (which is able to bind all class IA PI(3)K subunits bound to their 
regulatory adaptors) were then used in in vitro kinase assays using PIP2 as substrate. 
Total cellular class IA PI(3)K activity in these experiments was reduced by up to 
90% in p i 105D910A/D910ABMMCs, indicating that p i 108 contributes substantially to 
the overall class IA PI(3)K activity in these cells (Fig 3.2c).
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Fig 3.2 p i 105 is the principal class IA PI3K isoform in BMMCs (Experiments 
were carried out with help from Dr. Antonio Bilancio, Ludwig Institute for Cancer 
Research, London), a, WT and p i  10(P910A/D910A BMMC expression o f class IA 
PI(3)K subunits, b, p i 108 lipid kinase activity was assessed following 
immunoprecipitation o f class IA PI3K subunits with isoform-specific antibodies, c, 
Total class IA lipid kinase activity associated with YpVPMLG (where Yp is 
phosphotyrosine) peptide complexes.
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3.2.3 Differential requirement for p llO S  activity by mast cell growth 
factor receptors
Activation of growth factor receptors recruits PI(3)K activity which drives important 
signalling pathways with influence over cell proliferation, survival and activation 
(Carpenter and Cantley 1996; Fruman, Meyers et al. 1998; Vanhaesebroeck, Leevers 
et al. 2001). PI(3)Ks associate with receptors via phosphorylated tyrosine residues 
within the sequence YxxM (where x is any amino acid) found on receptors and 
receptor-associated adaptor proteins. Receptor PI(3)K association may be direct 
receptors (as is the case for Kit) or indirect (as in the case downstream of IL-3 and 
FcsRI) via adaptor proteins such as Gab2 or IRS (Wymann, Zvelebil et al. 2003).
To assess the impact of p i 108 inactivation on intracellular signalling we monitored 
PI(3)K-dependent phosphorylation pathways including phosphorylation of Ser 473 
of protein kinase B (PKB, also known as Akt) and Tyr 204 of Erk.
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3.2.3.1 PI(3)K signalling downstream o f  IL-3 is partially p i  1 OS-dependent 
We found that IL-3-induced PKB phosphorylation was only partially p i 105- 
dependent (Fig 3.5). In contrast to PKB, IL-3-induced phosphorylation of Erk was 
not affected by inactivation of p i 105 (Fig 3.3a). In analogy with this genetic 
inactivation of p i 105, acute inhibition of p i 105 in wild-type cells using the p i 105- 
selective pharmacological inhibitor IC87114 led to a dose-dependent inhibition of 
PKB phosphorylation following IL-3 stimulation, with a leveling off of the 
inhibition, leaving a substantial signal of PI3K activation even at the highest doses 
of IC87114 tested (30 pM, Fig 3.3b). This residual phospho-PKB signal generated in 
the absence of p i 105 activity remained sensitive to treatment with LY294002 and is 
therefore most likely a result of PI(3)K input, the nature of which remains to be 
clarified.
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Fig 3.3 IL-3 signalling in BMMCs is partially p i 105-dependent. (Experiments 
were carried out with help from Dr. Antonio Bilancio, Ludwig Institute fo r  Cancer 
Research, London), a, IL-3-induced PKB phosphorylation in p llO tf>910A/D910A 
BMMCs. by Acute p i  108 inactivation in WT BMMC mimics genetic inactivation.
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3.2.3.2 p i  105 is critical fo r PI(3)K signalling downstream o f the Kit receptor 
In contrast to what was seen for IL-3, SCF-induced PKB phosphorylation was 
almost completely abrogated in p i ioSD910A/D910A BMMCs (Fig 3.4a). The main 
product of class I PI(3)K activity is the inositol lipid PIP3 which is critical for 
recruiting of PKB to membrane sites where it is phosphorylated by the PI(3)K- 
dependent protein kinase (PDK1). Whereas PKB phosphorylation provides an 
indirect measure of PI(3)K activation, quantitation of total PIP3 levels is a more 
direct measure. We therefore determined PIP3 generation upon SCF stimulation and 
found that p i 105D910A/D910A BMMCs failed to produce PIP3 upon stimulation with 
SCF, confirming that p i 108 is critical for SCF-stimulated PI(3)K activity as 
revealed by the PKB phosphorylation read-out (Fig 3.4b).
Continuing to use PKB phosphorylation as a surrogate marker of PI(3)K activation 
we were further able to mimic these genetic defects in WT cells by the p i 1 OS- 
selective inhibitor IC87114 (Fig 3.5a). Treatment of WT BMMCs with IC87114 led 
to a dose-dependent reduction in PKB phosphorylation. At doses which are p i 108- 
selective (5-10 pM), IC87114 could completely abrogate PKB phosphorylation over 
a prolonged period of time (Fig 3.5b) (Sadhu, Masinovsky et al. 2003). We also 
tested whether IC87114 has any effect on JNK phosphorylation and report that 
unlike PKB, phosphorylation of JNK is partially inhibited by IC87114.
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Fig 3.4 p i 105 is critical for Kit receptor PI(3)K activity, a, WT p i  10(?>910A/D910A 
and BMMC stimulated with SCF b, in vivo PIP3 levels induced by SCF stimulation. 
The experiment shown in (b) was carried out with help from Dr Alex Gray, Dundee 
University, UK.
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Fig 3.5 Acute pharmacological p i 108 inactivation mimics genetic inactivation of
p i 108 (experiments were carried out with help from Dr. Antonio Bilancio, Ludwig 
Institute for Cancer Research, London) . a, WT BMMCs, pre-treated (30 min) with 
increasing concentration ofIC87114, were stimulated SCF for 5 min. b, Effect o f  
IC87114 on SCF-induced phosphorylation o f PKB and Erk.
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3.2.4 p i  10 8  is essential for mast cell proliferation and expansion
3.2.4.1 Proliferation
PI(3)K activity is essential for mast cell proliferation driven by IL-3 and SCF. 
Broad-spectrum PI(3)K inhibitors (LY294002 and wortmannin) substantially have 
been reported to attenuate the response of mast cells to both of these growth factors 
(Scheid, Lauener et al. 1995; Scheid and Duronio 1998; Lu-Kuo, Fruman et al.
2000; Fox, Crew et al. 2005). Recently two independent studies documented that 
deletion of PIK3rl regulatory subunits has no impact on IL-3-stimulated mast cell 
proliferation (assessed using DNA synthesis as a measure) (Lu-Kuo, Fruman et al. 
2000; Fukao, Yamada et al. 2002). In contrast, both studies linked PI(3)K coupled to 
p85a as important for SCF-induced proliferation (Lu-Kuo, Fruman et al. 2000; 
Fukao, Yamada et al. 2002). Overall current data suggest that the PI(3)K input 
which drives IL-3-stimulated proliferation (thought to be class IA PI3K- 
independent) is distinct from that which promotes SCF induced proliferation (class 
IA PI3K-dependent).
Using a similar strategy (DNA synthesis) we assessed the contribution of p i 108 
towards mitogen-stimulated proliferation (Fig 3.6), and found that genetic or acute 
pharmacological inactivation of p i 108 led to a partial block (up to 50%) in DNA 
synthesis induced by IL-3 (Fig 3.6). In contrast, proliferation induced by ligation of 
the Kit receptor was found to be almost completely reliant on pi 108 activity (Fig 
3.6).
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Mast cell homeostasis in vivo is under the influence of multiple cytokines, with the 
SCF/Kit interaction being a critical regulator which is further influenced by T cell- 
derived cytokines within the local tissue environment or released as part of the 
pathogenic response. Indeed, such Th2 cell factors such as IL-3 can synergise with 
SCF to promote rapid mast cell proliferation (Metcalfe, Baram et al. 1997). We 
investigated the co-stimulatory effects of IL-3 in combination with SCF and found 
that the dramatic synergy in WT cells is substantially attenuated upon p i 105 
inactivation (Fig 3.6).
Our data indicate that p i 105 drives proliferation downstream of both IL-3 and Kit 
receptors. Inactivation of p i 105 compromises the mast cell’s ability to proliferate to 
each factor on its own, a defect which cannot be overcome by co-stimulation with 
these two important mast cell growth factors.
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Fig 3.6 p i 105 is essential for mitogen-stimulated proliferation. WT and
p i  10dP910A/D9WA BMMCs were starved ofIL3 and SCF fo r  24 h in complete medium 
(containing serum), pre-treated (30 min) with or without IC87114 and stimulated 
with IL3 (a) SCF (b) or IL-3 and SCF (c)for 24h.
3.2.4.2 Expansion
Mast cells are long-lived cells which retain the ability for expansion following 
appropriate simulation. In vitro generated BMMCs also retain the capacity for cell 
division over prolonged periods of time.
We found that p i 105D910A/D910Abone-marrow progenitors supplemented with IL-3 
gave rise to substantially less BMMCs after a 4-6 week maturation period. Analysis 
of DNA-synthesis confirmed that part of this defect relates to substantially reduced 
responsiveness to mast cell growth factors.
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We next assessed how the partial defects in proliferation correlate to BMMC 
expansion. In order to circumvent any unappreciated differentiation defects we 
assessed this parameter in WT cells stimulated with IL-3 alone, or with IL-3 in 
combination with SCF, with or without IC87114/LY294002 for 4 days after which 
the numbers of viable cells were determined. We found that IC87114 (5 pM) could 
partially attenuate mast cell expansion in the presence of IL-3 alone. Similar to what 
we observed for proliferative responses, IL-3-stimulated expansion was substantially 
reduced but not abrogated upon pi 108 inactivation.
The capacity of co-stimulation of IL-3 with SCF (more representative o f the in vivo 
context where SCF is the primary cytokine which maintains homeostasis by acting 
as a survival factor which can potently synergise with Th2 cytokines to promote 
rapid mast cell expansion) to expand cell number was substantially reduced but not 
abrogated in the presence of IC87114 (Fig 3.7b). We also tested the effect of 
LY294002 (20 pM) under similar conditions and found that this broad-spectrum 
PI(3)K inhibitor can completely abrogate mast cell expansion after a 4 day period. 
This severe disruption of expansion was also associated with a reduction in the 
number of viable mast cells, indicative of an increase in apoptosis. Remarkably, 
increased apoptosis was not seen in cells treated with IC87114 (Fig 3.7).
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Fig 3.7 Delayed mast cell expansion upon acute inhibition of p i 108. BMMCs 
were starved overnight in complete medium (without growth factors but with serum), 
pre-treated with or without IC87114 / LY294002 (30 min) and stimulated with 20 
ng.m l1 IL-3 (a) or 20 ng.m l1 IL-3 and 20 ng.m l1 SCF (b) fo r  96 h after which the 
number o f viable cells were determined using a Casy counter.
3.2.5 p i  105 is critical for SCF-dependent mast cell adhesion
Mast cells are tissue-resident leukocytes for which adhesion is important to both 
homeostatic localisation and maintenance in the local environment. Mast cells in the 
local tissue environment are surrounded by SCF which is important for their survival 
and proliferation (Metcalfe, Baram et al. 1997). SCF interaction with its receptor Kit 
enhances mast cell adhesion and is a PI(3)K-dependent process (Dastych and 
Metcalfe 1994; Serve, Yee et al. 1995; Vosseller, Stella et al. 1997; Tan, Yazicioglu 
et al. 2003). We investigated mast cell adhesion to fibronectin (as a measure of 
activity of mast cell integrins) following SCF stimulation. SCF-stimulated BMMCs 
in which p i 108 has been genetically or pharmacologically inactivated exhibited a
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substantially diminished ability to adhere to fibronectin. Furthermore no additional 
impact on adhesion was seen when cells were incubated with LY294002, confirming 
that the total PI(3)K input in SCF-stimulated adhesion is provided by p i 106 (Fig 
3.8)
^  W T  Q  P 1 1 0 8 D910A/D910A
1 10 20 
SCF (ng/ml)
3v®
SCF
IC87114
LY294002
Fig 3.8 SCF-induced mast cell adhesion is p i 106-dependent, a, SCF-stimulated 
adhesion to fibronectin was measured in WT and pllO?P910A/D910A BMMCs. Genetic 
inactivation o f p i  1 OS leads to a substantial defect in basal (unstimulated) and SCF- 
stimulated cell adhesion, b, Acute inactivation o f p i  1 OS in WT cells with IC87114 (5 
jjM -3 0  min pre-incubation) .
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3.2.6 p i  1 OS is critical for SCF-dependent mast cell migration
Migration is important for both homeostatic localisation and infiltration to sites of 
inflammation. SCF is important for correct tissue localisation of mast cell 
progenitors (Meininger, Yano et al. 1992; Galli, Tsai et al. 1993; Nilsson, Butterfield 
et al. 1994; Metcalfe, Baram et al. 1997). SCF is known to stimulate mast cell 
migration (Meininger, Yano et al. 1992). Using a transwell system we assessed mast 
cell migration towards SCF and found that p i io§D910A/D910A BMMCs have a 
profound defect in migration towards an SCF gradient (Fig 3.9).
|  W T  Q  P1105D910A/D910A
SCF: " +
Fig 3.9 SCF-dependent mast cell migration is p i 105-dependent. Migration o fW T  
a n d p llO f>910A/D910A BMMCs was assessed in transwell (8 fjM) chambers in which 
BMMCs were placed in the top chamber were allowed to migrate towards an SCF 
(100 ng.ml1) gradient in the bottom chamber fo r  2.5 h. p i  10 f >910A/D910A.
3.2. 7  pllO (P910AD910A mice have site-selective loss o f mast cells
Mast cells originate within the bone marrow and are released as immature progenitor 
cells which migrate and mature within the peripheral tissues (Metcalfe, Baram et al.
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1997). We assessed the in vivo consequence of constitutive pi 108 inactivation on 
tissue mast cell numbers by histological analysis (Fig 3.1.1 -  these experiments were 
carried out with substantial help from Dr. Nicolas Kuehn at Frimorfo Inc, Fribourg,
Switzerland). Mast cell numbers in pi 108D910A/D910A mice were differentially
affected in distinct anatomical locations, with defects ranging from severe 
(peritoneum, jejunum, ileum and colon) over moderate (ear dermis, stomach sub­
mucosa and muscularis) to no significant differences (back dermis, mucosa of the 
stomach) (Table 3.1).
WT p1108D910A/D910A
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Fig 3.1.1 Site-selective reduction of mast cells in puo8D910A/D910A mice. Mast cell 
numbers were determined in WT and pllO fP910A/D910A mice by staining o f tissue 
sections with toluidine blue). pllO (P910A/D910A mice have reduced numbers o f  mast 
cells in the ear dermis but not in the back skin. Arrows, epidermis; arrowheads, 
cartilage; star, hair follicles with sebaceous glands.
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Table 3.1: Mast cell tissue distribution in WT and p iio8D910A/D910A mice
Mast cells/unita
WT pjjQgD9i0A/D9i0A o/Q reduction t-test
bperitoneum 27.7 ±4.17 2.13 ±0.76 92.2 p<0 . 0 0 1
ear dermis 184.2 ±35.63 97.17 ± 17.81 47.2 p<0 . 0 0 1
back dermis 40.2 ±3.27 34.2 ± 7.20 14.2 ns
stomach: mucosa 67.4 ± 15.69 60.33 ±23.16 10.5 ns
stomach: sub-mucosa 159.6 ± 14.5 91.67 ± 16.54 42.6 p<0 . 0 0 1
stomach: muscularis 76.4 ± 12.05 43.5 ±16.5 43.1 p<0.004
Jejunum 4.6 ±2.07 1.17 ± 1.60 74.1 p<0 . 0 1 2
Ileum 3.2 ±6.1 0.17 ±0.41 94.8 ns
Colon 2.4 ± 1.82 0 ± 0 100 p<0.016
aUnit: Ear dermis: per 5 mm length, beginning at the ear tip; back dermis: unit is
per 10 high power fields (40x objective = 400x magnification); stomach: per one 
complete sagittal section; jejunum, ileum, colon: per 6  cross sections (distance of 
50 pm between each section). Mast cell numbers in these locations were determined 
on toluidine blue-stained tissue sections, lu m b e rs  are per 1 0  fields view under a 
2 0 0 x magnification determined on alcian/blue safranin-stained cells, from cytospins 
of peritoneal flushes from WT mice (n=3) or pi io 8 D910A/D910A mice (n=3). Data are 
presented as the mean ± S.D. from n=5 for WT and n= 6  for p i 108D910A/D910A mice.
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3,3 Discussion
The primary effector through which PI(3)K can influence mast cell homeostasis 
appears to be the Kit receptor (Kissel, Timokhina et al. 2000; Fukao, Yamada et al. 
2002). Disruption of Kit/PI(3)K associations through mutagenesis of the PI(3)K 
binding site in the Kit receptor (tyrosine 719) or deletion of the most abundantly 
expressed class IA regulatory subunit (p85a) has been reported to lead to site- 
selective loss of mast cell populations, primarily within the peritoneum and gastro­
intestinal tract. BMMCs derived from these mice in vitro have attenuated SCF- 
induced responses including proliferation and survival (Kissel, Timokhina et al. 
2000; Lu-Kuo, Fruman et al. 2000; Fukao, Yamada et al. 2002).
A common theme in all of the published PI(3)K genetic models is disruption of 
expression of the non-targeted subunits, including the catalytic as well as the 
regulatory subunits (Vanhaesebroeck, Ali et al. 2005). There is now sufficient 
evidence to suggest that these strategies have disrupted two distinct aspects of 
PI(3)K biology, namely p i 10 kinase activity and p85 (and p i 10) kinase-independent 
protein-protein interactions. The importance of each of these features to how PI(3)K 
functions remains to be established. We have focused our efforts to understand the 
role of PI(3)K pi 10-kinase functions and have utilised a genetic model in which 
p i 106 expression is maintained but in which the kinase lacks catalytic activity. Our 
work thus describes a set of phenotypes which can exclusively be ascribed to the 
kinase activity o f p i 106.
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BMMCs derived from these p i io5D910A/D910A mice following a 4-6 week culture 
period have no obvious differentiation defects and express similar levels of Kit and 
FceRI receptors as WT BMMCs. However, we cannot rule out a differentiation 
defect as we have only assessed a limited number of mast cell markers. A more 
extensive analysis of receptor and protease expression is required in order to 
completely rule out any differentiation defects. It might also be of interest to carry 
out a gene profile analysis for example by array analysis.
We found that p i 105 is the principal class IA PI(3)K in mast cells. Indeed, 
inactivation of p i 105 leaves only residual PI(3)K lipid kinase activity towards PIP2 , 
most likely contributed by p i 10a and pi 10p. It is possible that the expression of the 
latter isoforms is much lower than that of p i 105. Unfortunately the current tools do 
not allow for accurate quantitation of PI(3)K isoforms. Available antibodies confirm 
expression of these proteins but cannot easily be used for comparative studies to 
determine relative levels of each PI(3)K isoform. Each polyclonal antibody used for 
detecting PI(3)K isoforms is comprised of a mixture of antibodies (directed against a 
common antigen) derived from B cell clones (directed against different epitope) 
each with its own affinity for the protein of interest. This difference in affinity is 
magnified between different polyclonal antibodies and cannot be standardised.
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3,3.1 IL-3-associated PI(3)K activity
IL-3-stimulated BMMC proliferation is LY294002 sensitive, however when we 
initiated this work, there was no direct genetic evidence to suggest the involvement 
of class IA PI(3)Ks in this response. Indeed, deletion of major class IA regulatory 
subunits was reported to have no affect on IL-3-induced proliferation or survival 
(Lu-Kuo, Fruman et al. 2000; Fukao, Yamada et al. 2002). In contrast, our data 
indicate that p i 108 activity has an important but non-exclusive role downstream of 
the IL-3 receptor and partially drives the PI(3)K- dependent IL-3-induced 
proliferation and expansion. Our data are consistent with work in which a dominant- 
negative class IA PI3K construct (Ap85, which is unable to interact with p i 10 
subunits) was expressed in BMMCs and the IL-3- dependent cell line Baf/3 (Fox, 
Crew et al. 2005). Expression of Ap85 was found to delay cell cycle progression 
through the G1 phase upon stimulation by IL-3, implicating that class LA PI(3)Ks are 
important for optimal cell cycle progression in response to this cytokine (Fox, Crew 
et al. 2005). These data support our own observations that inactivation of p i 108 
activity delays rather than blocks cell proliferation and expansion. The delay in 
expansion appears to be modest but amplified over a period of time maybe sufficient 
to substantially impact mast cell numbers and may explain why we obtain a lower 
yield of BMMCs after a 4-6 maturation of pi io 8 D910A/D910A bone marrow 
progenitors.
An important question which remains to be answered is the nature of the PI(3)K able 
to maintain mast cell homeostasis in the absence of p i 108 activity. Unlike tyrosine
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kinase receptors, the IL-3 receptor recruits PI(3)K activity indirectly via scaffold 
proteins including Gab2. Thus it maybe that scaffold proteins recruit other class IA 
PI(3)K isoforms including p i 10a and pi 10(3, which can maintain in vitro mast cell 
cultures. It is also possible that the IL-3 receptor can recruit other classes of PI(3 )K.
It is important to mention here that non-PI(3)K pathways, such as the Erk pathway, 
are unaffected by loss of p i 105 activity. These pathways most likely are also critical 
for mast cell homeostasis in vivo.
3.3.2 Kit receptor-associated PI(3)K activity
Our data indicate that p i 105 is critical for Kit-receptor-associated PI(3)K activity. 
Inactivation of p i 105 led to a complete abrogation of SCF-induced PIP3 production 
and a similar reduction in PKB phosphorylation. The functional consequences of this 
drastic loss of PI(3)K activity are severe defects in SCF-induced proliferation, 
adhesion and migration. These findings imply that unlike the IL-3 receptor which 
can utilise multiple PI(3)Ks, the Kit receptor preferentially utilises p i 105 to drive 
PI(3)K-dependent functional responses. Why then does the Kit receptor not utilise 
other sources of PI(3)K? It has been shown that Gab2 can recruit to the Kit receptor 
and provide PI(3)K input which can augment the sustained phase of PI(3)K activity 
(Nishida, Wang et al. 2002). Loss o f Gab2 leads to a partial reduction in SCF-driven 
proliferation (at high doses of SCF) and a more transient PKB phosphorylation 
(Nishida, Wang et al. 2002). Like other adaptors that bind PI(3)K, Gab2 has no 
known selectivity for PI(3)K isoforms and can associate with all class IA PI(3)K 
subunits. Genetic modification of tyrosine-719 on the Kit receptor has been reported
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to lead to complete abrogation of Kit/PI(3)K association and activity (Kissel, 
Timokhina et al. 2000). As this mutation is not expected to directly affect Gab2 
signalling it is surprising that BMMCs derived from KitY719F/ KitY7l9Fmice do not 
recruit Gab2-associated PI(3)K. Thus, tyrosine-719-associated PI(3)K appears 
important for recruiting a second phase of PI(3)K (possibly Gab2-associated) which 
increases the amplitude and duration of PI(3)K activity. Clearly both phases of 
PI(3)K activity are important for mast cell homeostasis as both Kit719F/719F and Gab2 
KO mice have similar mast cell tissue distribution defects (Fig 3.1.2) (Kissel, 
Timokhina et al. 2000; Gu, Saito et al. 2001; Nishida, Wang et al. 2002).
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Fig 3.1.2 Comparison of mast cell tissue distribution of different mutant mice. A
comparison o f mast cell tissue distribution from mutant mice in which PI(3)K (p85a 
and p i  105), PI(3)K-receptor binding site (Kit-tyrosine-719) or major PI(3)K 
scaffold (Gab2) proteins have been gene-targeted.
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3.3.3 Class IA p i  1 OS activity is important for maintaining the 
homeostasis o f  a subset o f  mast cells
The SCF/Kit interaction is the primary signal which maintains mast cell homeostasis 
in vivo (Metcalfe, Baram et al. 1997). Disruption of Kit kinase activity is known to 
lead to severe reductions in mast cell numbers in all anatomical locations (Metcalfe, 
Baram et al. 1997). Our data are in line with the hypothesis that PI(3)K activity 
downstream of the Kit receptor is important for maintaining the homeostasis of a 
certain mast cell subset(s). Recently it has been shown that the two forms of SCF 
(membrane-bound SCF, expressed on endothelial cells, fibroblasts, keratinocytes 
etc) and soluble SCF (cleaved from the surface of endothelial cells and fibroblasts) 
differentially utilise PI(3)K activity (Trieselmann, Soboloff et al. 2003). Therefore it 
is possible that mast cells residing in anatomical locations in which mast cell 
numbers are profoundly reduced, utilise (or have access to) primarily soluble SCF 
which would make these cells more sensitive to PI(3)K inhibition. We have not 
tested how BMMCs derived from p i 108D910AD910A mice respond to membrane- 
bound SCF. Future areas of investigation a more detailed analysis of in vivo mast 
cell tissue distribution and any differences in how membrane bound and soluble SCF 
utilise p i 108 activity.
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4.0 Role of pi 105 in the allergic response
4.1 Summary
PI(3)K has an important role downstream of the FcsRI receptor, as shown by the 
attenuation of degranulation by the broad-spectrum PI(3)K inhibitors LY294002 and 
wortmannin (Yano, Agatsuma et al. 1995). It was therefore remarkable that cells 
from mice with deletions in the PI(3)K regulatory subunits had no effect on mast cell 
degranulation and appeared even to have enhanced PI(3)K signalling pathways 
under certain conditions, for example downstream of the FcsRI (Lu-Kuo, Fruman et 
al. 2000; Vanhaesebroeck, Ali et al. 2005).
Using cells derived from p i 108D910AD910A mice and a p i 108-selective small 
molecule inhibitor, we have assessed the contribution of the p i 105 isoform 
downstream of IgE/antigen-triggered mast cell responses. We found that inactivation 
of p i 105 led to substantial attenuation of PI(3)K-dependent PKB phosphorylation, 
mast cell degranulation and a reduction in the release of the pro-inflammatory 
cytokines TNFa and IL-6 . In addition, calcium flux (a pre-requisite for optimal 
degranulation) was substantially reduced in p i 108D910AD910A BMMCs.
Human mast cells, pre-incubated with the p i 108 inhibitor IC87114 at a 
p i 108-selective dose, showed attenuated FcsRI receptor-induced degranulation 
Furthermore in a more physiological context, IC87114-treated human mast cells
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stimulated with a sub-optimal dose of antigen in presence of SCF have a more 
severe attenuation of the exocytosis response.
p i io 5 D910AD910A mice had a substantially diminished IgE-dependent passive 
cutaneous anaphylaxis (PCA) response which could also be mimicked by treating 
wild-type mice with IC87114 at a dose which is selective for p i 108. The PCA 
response could be completely blocked at higher doses of IC87114 at which this 
compound may also block PI(3)K isoforms other than p i 108.
We conclude that p i 108 together with other PI(3)K(s) is essential for driving 
IgE/antigen-dependent mast cell degranulation. Genetic or pharmacological 
inactivation of p i 108 leads to a substantial reduction in mast cell degranulation 
which at the whole animal level can attenuate the allergic immune response.
4.2 In vitro allergic immune response
4.2.1 p i  108 activity is essential fo r  FcsRI signalling
Mast cells respond to specific antigen as part of the allergic response which is 
directed through the high affinity receptor for IgE (FcsRI) (Metcalfe, Baram et al. 
1997; Wedemeyer and Galli 2000; Puxeddu, Piliponsky et al. 2003; Blank and 
Rivera 2004). The FcsRI binds antigen-specific IgE which responds to antigen 
cross-linking by activating a series of intracellular cascades leading to degranulation 
and cytokine release. PI(3)K activity has been identified as being essential for mast 
cell degranulation (Yano, Agatsuma et al. 1995; Ching, Hsu et al. 2001; Smith,
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Surviladze et al. 2001; W indmiller and Backer 2003). PKB phosphorylation on 
Ser473 or Thr308 serves as an indirect measure o f  PI(3)K activity and we have 
shown that this can be used as a reliable measure o f  PI(3)K status within BM M Cs 
(see section 3.2.3). We found that PKB phosphorylation following antigen cross- 
linking is substantially reduced upon genetic inactivation o f p i 108 (Fig 4.1). In 
contrast, Erk/M APK phosphorylation was found to be unaltered (Fig. 4.1).
Time WT p1105D910/VD910A
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Fig 4.1 p i 108 is essential for FcsRI-stimulated PI(3)K activity. WTand
pllQ (P9l0AD910A BMMCs werepre-incubated overnight with monoclonal anti-DNP 
IgE Clone SPE-7 (1 mg. m l1) and challenged the following day with antigen (anti- 
DNP HSA, 100 ng.mt1) for the indicated times, followed by immunoblotting o f cell 
extracts for the indicated signalling molecules.
4.2.2 In vitro activation o f  murine BMMCs
Using an in vitro degranulation assay and P-hexosaminidase activity (an intracellular 
granule-associated enzyme released as part o f the exocytosis process) to measure
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this response, we assessed the impact of p i 108 inactivation on IgE/antigen-triggered 
specific immune responses in BMMCs (Fig 4.2a). Following sensitisation with 
antigen-specific IgE (specific for the hapten dinitrophenol), BMMCs were triggered 
to release intracellular mediators upon subsequent exposure to antigen 
(dinitrophenol coupled to BSA). Genetic or pharmacological inactivation of p i 108 
led to a substantial (-40-50%) reduction in the IgE/antigen-triggered mast cell 
exocytosis response, a defect which is maintained across a broad-range of antigen 
concentrations tested (Fig 4.2b).
The residual response remaining in p i io 8 D910A/D910A BMMCs could be further 
inhibited to a maximum of 80% by treatment with LY294002 (Fig 4.2a). These 
findings suggest that there is a LY294002-sensitive pool of PI(3)K which 
contributes towards the exocytosis process and is responsible for maintaining the 
partial PI(3)K-dependent degranulation response in p i 108D910A/D910A BMMCs, 
accounting for -35%  of the overall degranulation response. The remaining 
LY294002-insensitive in vitro degranulation response (-25% of the total response 
(Fig4.2a)) appears not to depend on PI(3)K activity and may be a consequence of the 
activation of other signalling pathways, such as the PLCy pathway. IC87114 can 
substantially attenuate the degranulation of WT BMMC but has no additional effects 
on the exocytosis response of p i io 8 D910A/D910A BMMC confirming that this 
compound is on target (Fig 4.2c).
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Fig 4.2 p i  105 is essential for degranulation of mouse mast cells, a, Exocytosis 
was measured ({3-hexosaminidase release from mast cell granules) in exponentially 
growing WT and pll0<P910A/D9l0A BMMCs pretreated with or without LY294002 (30 
pM  for 30 min) and stimulated with IgE/antigen complex. Degranulation is 
expressed as percent o f total cellular {3-hexosaminidase, b, WT and p llO fP 910AD910A 
BMMCs pre-incubated with 1 mg.mt1 o f  IgE were stimulated by varying 
concentrations o f  antigen, followed by measurement o f  (3-hexosaminidase release. 
Cylmpact ofIC87114 was assessed in WT and p llO lP 910A/D910A BMMC which were 
pre-incubated with or without IC87114 (5 juM).
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4.2.3 Cytokine production by BMMCs
A consequence of IgE/antigen-triggered mast cell degranulation is the release of
extracellular cytokines (Galli, Kalesnikoff et al. 2005). We measured the release of
TNFa and IL-6 , two important pro-inflammatory cytokines, and found that
p i 1 0 SD910A/D9I0A BMMCs released substantially reduced amounts of these factors
upon IgE/antigen activation (Fig 4.3).
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Fig 4.3 Reduced release of pro-inflammatory cytokines upon FcsRI ligation in
pll08D910A/D910A BMMCs. W T andpi 10dP9WAD910A BMMCs were activated with 
IgE/Ag complex fo r  1 h after which cytokine levels were determined in supernatants.
4.2.4 Calcium flux in BMMCs
Calcium mobilisation is a prerequisite for the degranulation response and has two 
distinct phases, namely first calcium release from intracellular stores followed by 
influx of calcium from the extracellular environment (Yano, Agatsuma et al. 1995; 
Ching, Hsu et al. 2001; Smith, Surviladze et al. 2001; Windmiller and Backer 2003; 
Blank and Rivera 2004).
TNFa IL-6
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Calcium release following IgE/Ag cross-linking in pi 1 o5D910A/D910A BMMCs was 
substantially but not completely ablated (Fig 4.4).
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Fig 4.4 p i 108 activity is im portant for IgE/Ag-activated calcium flux in 
BMMCs. W Tandpi 10<f9WD9WA BMMCs preloaded with Fluo-4 were activated 
with IgE/Ag in 96-well plates (2 X  10s cells per well). Intracellular calcium flux was 
followed over time by measuring fluorescence emission at 520 nM.
4.2.5 In vitro activation o f  human mast cells (experiment carried out by 
Christine Tkaczyk and Alasdair M. Gilfillan, NIH, USA)
Using IC87114, our collaborators in the US assessed how our data obtained from 
mouse BMMCs compared with the human system. Similar to what we found in 
murine BMMCs, acute pharmacological inactivation of p i 108 in human mast cells 
resulted in a -40% reduction in mast cell degranulation. This attenuated human mast
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cell degranulation could be further reduced by treatment with LY294002 (Fig. 4.5a), 
indicative that multiple PI(3)Ks drive human mast cell degranulation.
In vivo, mast cell activation occurs in an SCF-rich environment. SCF has been 
shown to augment the IgE/antigen activation response (Vosseller, Stella et al. 1997). 
A more physiologically relevant assay therefore is the measurement of mast cell 
activation in vitro by a low concentration of antigen in the presence of SCF. It is 
clear that under these conditions, pharmacological inactivation of p i 108 led to a 
very substantial defect in the exocytosis response (Fig 4.5b).
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Fig 4.5 pi 108 is essential for human mast cell degranulation, a, Human mast 
cells were sensitized with IgE overnight and challenged with antigen (1 ng.m l1)  
following 30 min pre-incubation with or without LY294002 (30 pM) or IC87114 (5 
pM). b, IgE-sensitized human mast cells, pre-incubated with or without IC87114 (5 
pM) or LY294002 (30 pM), were challenged with sub-optimal concentrations o f  
antigen (0.1 ng.m l1) in the presence o f  varying does o f  SCF.
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4.3 In vivo allergic immune responses
4.3.1 Passive cutaneous anaphylaxis
We next investigated the impact of p i 108 inactivation on allergic responses in a 
murine model of anaphylaxis. In vivo anaphylaxis through the FcsRI receptor is an 
allergic response that is predominantly mast-cell-dependent and occurs as a result of 
either local or systemic exposure to allergens, which crosslink and activate antigen- 
specific IgE bound to the FcsRI on the mast cell surface (Wedemeyer and Galli 
2000). We assessed the capacity of wild-type and p i io8D910A/D910A miCe to respond 
to immune challenge in a passive cutaneous anaphylaxis (PCA) model. Mice were 
given an intradermal injection of IgE directed against a hapten (dinitrophenyl (DNP) 
in this case). 24—48 h after this priming event, the mice were challenged by systemic 
administration of DNP coupled to a carrier protein (HSA) together with Evan’s blue 
dye, which binds to serum proteins. Mediators released upon mast cell activation 
increase vascular permeability, causing oedema and allowing the dye to leak from 
the blood vessels into the surrounding tissue. The amount of extravasated Evan’s 
blue provides an indirect measure of mast cell activation. We assessed the PCA 
response in two distinct tissue locations. In the ear of p i io8D910A/D910A mice, a 
marked (80%) reduction in PCA was observed. This decrease was more significant 
than the reduction in mast cell numbers at this location (maximally 47% - Table 3.1), 
suggesting that the remaining mutant mast cells may be defective.
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The PCA reaction in the back dermis, a site with unaltered mast cell numbers in 
p ll0 8 D910A/D910A mice (Table 3.1), was also significantly reduced (40%, see Fig 
4.5b).
IC87114, at doses at which it is selective for p i 108 (plasma concentration of 5 pM 
from a 15 mg kg- 1  dose), reduced the allergic response by 35-40% in the back skin 
and ear of wild-type mice (Fig 4.6). At higher plasma concentrations (40 pM from a 
60 mgkg- 1  dose), IC87114 completely blocked the anaphylaxis reaction in the back 
dermis (Fig 4.6c). This may be a consequence of the inhibition of other PI(3)K 
iso forms (such as p i 10y), which could account for the remaining PI(3)K-dependent 
(that is, LY294002-sensitive) degranulation seen in p i 108D910A/D910A BMMCs (Fig. 
4.2a).Taken together, our data show that this class of small molecule inhibitors of 
PI(3)K can completely abrogate in vivo cutaneous anaphylaxis.
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Fig 4.5 p i  108 is essential for the allergic immune response (experiment carried 
out with help from Wayne Pearce , Ludwig Institute for Cancer Research, London, 
and Matthew Thomas, Novartis, Horsham, UK) a, PCA response (ear) o fW T  
(n=13) and p i  10(P910A/D910A mice (n—10). b, PCA response (back skin) o f  mice 
injected with anti-DNP IgE, challenged with saline (n=4 fo r  WT; n=5 fo r  
p U 0 f 9,0A,D9,0A) or DNP-HSA (n=5for WT; n = 6 f o r p l l 0 ^ loAJD9,OA). c, IC87114 
attenuates the PCA response (back skin) o fW T mice (n—8 fo r each treatment 
group).
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4.3.2 Passive systemic anaphylaxis
Systemic exposure of antigen to a sensitized individual leads to anaphylaxis which 
can be life-threatening and a consequence of mast cell activation leading to vascular 
collapse (Wedemeyer and Galli 2000). Sensitization of mice via systemic 
administration of antigen-specific IgE followed 24 h later via systemic 
administration of antigen leads to an anaphylactic response which can be quantified 
by measuring vascular leakage and histamine release.
We assessed in vivo anaphylaxis in p i 10SD910A/D910A mice using histamine in the 
circulation as a measure of the response. However, our results have thus far been 
inconclusive. The main reason for this is that we observed a significantly higher 
basal level of histamine in p i io 8 D910A/D910A mice that were sensitized but not 
challenged with antigen (Fig. 4.7). If we take this higher basal histamine level into 
account, p i ioSD910A/D910A mice challenged with antigen following sensitization 
showed substantially reduced plasma histamine levels (-60% less then WT mice) 
(Fig 4.7). These data and possible reasons for the elevated histamine levels will are 
discussed in section 4.4.4.
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Fig 4.7 p ll08D910A/D910A mice have elevated basal histamine levels (experiment 
carried out with help from Wayne Pearce, Ludwig Institute for Cancer Research, 
London). WT andpllO tP 910AD910A mice were sensitized with IgE (2 jug) 24 h prior to 
challenge with antigen (500 pg) (n = 11 fo r  WT, n=9 fo r  p i  10(P9WAD910A) or saline 
(n =6 for WT, n=5 fo r  p i  10fP910AD9WA) (under terminal anaesthesia) fo r  2 min after 
which mice were sacrificed and terminal blood samples were taken fo r  plasma 
histamine analysis, a, Sensitized but unchallenged p i  10(f>9WAD9,OA mice have 
significantly elevated plasma histamine levels, b, Data from (a) presented as PSA 
response fo ld  over basal, this suggests that p i  10(P910A/D910A mice are less 
responsive to PSA challenge.
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4.4 Discussion
Previous work has revealed that genetic deletion of Gab2 one of two major 
scaffolding proteins (the other being LAT) recruited to FcsRI receptor complexes 
upon activation, removes a major platform through which FcsRI can gain access to 
class IA PI(3)Ks in BMMCs. Indeed Gab2 null BMMCs have a severe reduction (up 
to 80%) in FcsRI stimulated PI(3)K activity, a partial reduction in calcium flux and 
a substantial reduction (~65 % ) in degranulation (Gu, Saito et al. 2001). Gab2 null 
mice have impaired passive cutaneous and passive systemic anaphylaxis responses 
in vivo (Gu, Saito et al. 2001). These data led to the hypothesis that disruption of a 
sufficiently large quantity of class IA PI(3)K activity may mimic the defects of Gab2 
deletion and block IgE-dependent anaphylaxis in vivo. This hypothesis is supported 
by data from a number of other studies using broad-spectrum PI(3)K inhibitors, the 
pan-class IA Ap85 inhibitor construct and p i 10 isoform-specific neutralising 
antibodies (Yano, Agatsuma et al. 1995; Ching, Hsu et al. 2001; Smith, Surviladze et 
al. 2001; Windmiller and Backer 2003). We found that p i 108 contributes 90% of the 
total class IA PI(3)K activity in BMMCs (Fig 3.2c), allowing us to test the above 
hypothesis.
4.4.1 p i  1 OS activity is essential for in vitro mast cell activation
The data from our studies to a large extent support the above hypothesis. Indeed, 
genetic or pharmacological inactivation of p i 105 leads to substantial defects in 
IgE/antigen-stimulated PI(3)K activity (assessed using PKB phosphorylation) 
calcium mobilisation, cytokine release and mast cell degranulation.
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Our data provide a direct correlation between PI(3)K activity and BMMC 
exocytosis. We also show that this PI(3)K activity not only drives the exocytosis 
process but also the release of pro-inflammatory cytokines such as IL- 6  and TNFa 
the release of which is substantially diminsished upon IgE-antigen activation in the 
absence of p i 108 activity. It is therefore possible that p i 108 drives important 
pathways which lead to transcription and synthesis of these cytokines including 
NfkB and the JNK pathways and is an area which requires further investigation.
4.4.1.1 Model fo r  p i  108participation in mast cell degranulation
Broad-spectrum PI(3)K inhibitors can attenuate up to 80% of the IgE/antigen 
stimulated mast cell degranulation response (Fig 4.2a). To date no study has 
identified a component downstream of the FcsRI cascade critically dependent upon 
PI(3)K input. Calcium mobilisation is one of the degranulation ‘events’ found to be 
particularly sensitive to PI(3)K inhibitors. Our data confirm that p i 108 is important 
for calcium flux but does not identify a specific p i 108 target which can influence 
calcium flux.
Overall the literature points towards PI(3 )K/PIP3 being a facilitator of translocation 
events, bringing together the molecular machinery (including Tec family PTK, 
guanine nucleotide-exchange factors and others) and thereby assisting in the 
formation of a ‘signalosome’ which promotes calcium mobilisation, PKC activation 
and exocytosis.
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p i 108 activity may also activate plasma membrane calcium channels (either directly 
via PIP3 or indirectly by recruiting Tec family PTKs such BTK) which control 
calcium influx from the extracellular environment.
We have combined our observations from signalling and functional studies to 
propose a model for p i 108 participation downstream of the FcsRI, as shown in Fig 
4.8.
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Fig 4.8 PI(3)K is a facilitator. PI(3)K brings together different components o f  the 
calcium signalling cascade which together form a ‘signalosome ’ centred around the 
adaptor protein LAT.
4.4.1.2 p85 deletion does not disrupt PI(3)K activity
Our findings are in contrast to previously published data from p85 gene-targeted 
models. Partial or complete disruption of PIK3rl or PIK3r2 has no effect on 
IgE/antigen-stimulated mast cell calcium response or exocytosis. Paradoxically
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IgE/antigen-stimulated PKB phosphorylation in mast cells can be enhanced (in pan- 
p85a mast cells) or kinetically altered (in p85p null mast cells) suggesting that 
PI(3)K activity was certainly not reduced(Lu-Kuo, Fruman et al. 2000; Tkaczyk, 
Beaven et al. 2003). In other words mast cells derived from p85 KO models still 
have access to PI(3)K activity within FcsRI receptor complexes which is sufficient 
to drive PI(3)K dependent signalling pathways and mast cell exocytosis. The most 
likely explanation is that the remaining regulatory adaptor proteins (or up-regulation 
of the non-targeted isoforms) in p85 KO models can both stabilise and recruit 
PI(3)K compensating for the genetic deletions. This explanation suggests that class 
IA PI(3)K activity downstream of the FcsRI receptor has not been reduced in p85 
models.
Another explanation which has been put forward is that in p85 models there may 
exist a pool of ‘free’ p i 1 0  which may be recruited independently of regulatory 
subunits, possibly through their C2 domain or via activated Ras, however although 
this is possible, regulatory subunits also stabilise p i 1 0 , it is not clear how these 
‘free’ p i 10 subunits would be stabilised in such an environment(Lu-Kuo, Fruman et 
al. 2 0 0 0 ).
4 .4 .13  Residual PI(3)K activity downstream o f  FcsRI
p i io§D910A/D9,OA BMMCs have a residual degranulation response which remains 
partially PI(3)K-dependent (and drives -30% of the total degranulation event) and
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can be attenuated by broad spectrum PI(3)K inhibitors. The nature of the PI(3)K(s) 
which provide(s) this input into FcsRI responses remains unknown.
Possible PI(3)K candidates which sustain the remaining LY294002-sensitive 
fraction of the degranulation response in p i 108D910A/D910A and WT BMMC cells 
treated with IC87114 include p i 10a and p i 10(3 which may contribute sufficient 
PI(3)K activity by becoming recruited upon FcsRI ligation, despite the fact that they 
only appear to contribute to a minor extent to the overall class IA PI(3)K activity in 
BMMCs. Other candidates include the GPCR-coupled p i lOy which has also been 
implicated downstream of IgE/antigen responses (see section 4.4.5) and the other 
classes (class II, III) of LY294002-sensitive PI(3)Ks (Laffargue, Calvez et al. 2002; 
Windmiller and Backer 2003).
4.4.2 p i  108 activity is essential fo r human mast cell activation
Both human and murine mast cells treated with IC87114 have similar reductions in 
exocytosis. In a more physiological setting in which human mast cells are activated 
with suboptimal concentrations of antigen in the presence of SCF, exocytosis was 
more severely disrupted. As mast cells are maintained in the tissue environment by 
SCF/Kit interactions, our data suggest that within an in vivo context, p i 108 may 
have a more important role in influencing mast cell activation.
4.4.3 Class I  PI(3)Ks are essential for the in vivo allergic response.
Our data indicate that disruption of class I PI(3)K activity is sufficient to completely 
block the in vivo passive cutaneous anaphylaxis response. IgE/antigen activation of 
mast cells in vitro consists of two fractions, a PI(3)K-dependent fraction (80% of the
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total degranulation response) and PI(3)K-independent fraction (20% of the total) 
which is resistant to broad-spectrum PI(3)K inhibitors (Fig 4.2a). The PI(3)K- 
independent part of in vitro degranulation is thought to be driven by PLCy activity 
(Tkaczyk, Beaven et al. 2003). Our in vivo data indicate that any putative PI(3)K- 
independent PLCy activity may not significantly contribute towards mast cell 
activation in vivo, as under conditions of 40 pM plasma dose of IC87114, there was 
full abrogation of the measurable PCA response (Fig 4.5). In other words, we found 
that all degranulation in our in vivo experiments appeared to be PI(3)K-dependent. 
Although it remains possible that at 40pM IC87114 may have off-target effects 
(including PLCy) it would seem that within an in vivo context PI(3)K does have 
significant influence over PLCy activity. The difference between in vivo and in vitro 
data may be explained by subtle changes signalling pathways which may be a 
consequence of culture adaptation which lessen the requirement for PI(3)K input 
into the PLCy pathway.
4.4.4 Increased basal histamine levels in pllOfP910A/D910A mice
pi io 5 D910A/D910A mice passively sensitized with IgE but not challenged with antigen 
were found to have considerably higher levels of plasma histamine than equivalent 
WT mice (-58% above WT levels) (Fig 4.7). This result makes conclusions relating 
to systemic anaphylaxis experiments very difficult.
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4.4.4.1 Increased basal histamine as a consequence o f  reductions in 
IgE- binding cells and receptors.
Increased basal histamine levels in IgE-sensitized p i 108D910A/D910A mice which were 
not challenged with antigen maybe consequence of increased numbers of circulating 
immune complexes within these mice. It is known that monoclonal IgE can 
aggregate into immune complexes which can activate cells expressing FcsRI and 
FcyRIII receptors (Takizawa, Adamczewski et al. 1992).
p i io§D910A/D910A mice are known to have a reduction in mast cells and B cells both 
of which express receptors able to bind IgE. In addition B cells release a soluble 
form of the IgE receptor FcsRII (CD23) which may be reduced in p i 108D910A/D910A 
mice as a consequence of the B cell defect (Fremeaux-Bacchi, Fischer et al. 1998; 
Gould, Sutton et al. 2003). It is therefore possible these reductions in interacting 
cells and receptors within p i 108D910A/D910A mice results in increased plasma IgE 
levels (following passive sensitization) which may form immune complexes and 
activate histamine releasing cells such as mast cells and basophils.
4.4.4.1 Increased sensitivity to ‘cytokinergic ’properties o f  SPE-7 
monoclonal IgE antibody.
Another speculative explanation for the increased histamine levels in p i 108 mutant 
mice might relate to increased responsiveness of these mice to ‘cytokinergic’ 
signalling of the SPE-7 monoclonal IgE utilised in our studies. Indeed, mast cell
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interaction with this monoclonal IgE has been found to activate intracellular 
signalling cascades leading to functional responses (including survival and cytokine 
release), independently of antigen crosslinking (Kitaura, Song et al. 2003). However 
the pathway/cell which translates this feature of IgE into higher basal histamine 
levels in unchallenged p i 105D910A/D910A mice is at present unknown.
It is also possible that the p i 108 mutation results in subtle adaptation of the 
degranulation machinery, as occasionally increased basal (i.e. without IgE or 
antigen) degranulation in p i 108D910A/D910A BMMCs has been observed (data not 
shown, ~5% above WT levels). At present, it is not clear what causes this enhanced 
spontaneous in vitro degranulation and is another area which requires additional 
investigation.
4.4.4.3 Loss ofPI(3)K  activity leads to enhanced innate immune 
responses.
There is genetic and pharmacological data to suggest that PI(3)K may have a 
negative role in the regulation of innate immune responses (Fukao, Tanabe et al. 
2002; Guha and Mackman 2002; Schabbauer, Tencati et al. 2004; Aksoy, Vanden 
Berghe et al. 2005).
Pretreatment of dendritic cells with broad-spectrum PI(3)K inhibitors induces 
increased IL-12 release following stimulation with a variety of toll-like receptor 
ligands, including lipopolysacharide (LPS), peptidoglycan and CpG-oligodeoxy- 
nucleotide(Fukao, Tanabe et al. 2002). Dendritic cells derived from p85a null mice 
have a similar increase in IL-12 production. Furthermore macrophages treated with
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broad-spectrum PI(3)K inhibitors followed by LPS stimulation have an increased 
production of pro-inflammatory cytokines including IL- 6  and TNFa. Likewise, 
disruption of SHIP which is expected to result in an increase in PI(3)K activity has 
been reported to lead to a substantial reduction in the pro-inflammatory cytokines 
production in SHIP null macrophages (Guha and Mackman 2002; Fang, Pengal et al. 
2004; Schabbauer, Tencati et al. 2004). These data are indicative that at the 
organismal level PI(3)K may have a role in maintaining the Thl/Th2 balance 
(Fukao, Tanabe et al. 2002).
Mast cells express a range innate immune toll like receptors and have an important 
role in the host defence against bacterial infections; mast cells when exposed to 
bacteria release a range of inflammatory mediators (including leukotrienes, 
histamine and TNFa) which are important in recruiting leukocytes (such as 
neutrophils) and help resolve bacterial infections (Echtenacher, Mannel et al. 1996; 
Malaviya, Ikeda et al. 1996; Mannel, Hultner et al. 1996; Puxeddu, Piliponsky et al.
2003) (Malaviya, Ikeda et al. 1996; Malaviya and Abraham 2001).
If class IA PI(3)K, as has been suggested by some of the studies detailed above, has 
a negative role within the innate immune system (downstream of toll-like receptors) 
then inactivation of p i 106 may reflect a significant disruption of PI(3)K activity 
thereby enhancing innate immune receptor responses to bacterial infections. It is 
therefore possible that mast cells within p i 106D910AD910A mice have an enhanced 
responsiveness to endogenous gut bacteria which activate the liberation of mast cell
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products (including histamine) and may explain why these mice have an increased 
basal histamine levels.
4.4.5 Interaction between p llO yan dp llO S  in the allergic response?
In agreement with the essential role for p i lOy downstream of GPCRs, p i 10/ null 
mice are completely resistant to increases in vascular permeability induced by 
adenosine (Laffargue, Calvez et al. 2002) .
p i lOy is also essential for optimal IgE/antigen stimulated mast cell activation in 
which it participates by way of an autrocrine loop (Fig 4.9). IgE/antigen complexes 
activate a protein tyrosine cascade downstream of the FcsRI receptor leading to the 
recruitment of class IA PI(3)K activity, which is modulated by the action of the lipid 
phosphatase SHIP. This initial stage of mast cell activation leads to the liberation of 
intracellular adenosine (and other GPCR agonists) into the extracellular milieu. 
Adenosine acting through the A3-adenosine receptor stimulates a critical burst of 
p i lOy-derived PIP3 which is essential for sustained extracellular calcium influx and 
is sufficient to circumvent SHIP and thereby exacerbates the mast cell response 
leading to optimal mast cell activation.
The partial contribution of the p i 1 Oy-dependent autocrine loop towards IgE/antigen- 
stimulated in vitro BMMC degranulation is translated into a critical contribution 
within an in vivo context namely that p i lOy null mice are completely resistant to 
IgE/antigen-dependent passive systemic anaphylaxis challenge.
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These data attribute a similar function to p i lOy as the one we have described for 
p i 108, namely an important (indirect, in case of p i lOy) role downstream of the 
IgE/antigen-stimulated allergic cascade.
In order to resolve this issue it will necessary to carry out a parallel study on pi 108 
and p i lOy mutant mice under similar experimental conditions. However it is 
possible that both of these studies have confounded by additional variables. These 
include the loss of kinase-independent functions (in the p i lOy null mice) and by 
endothelial defects which may have masked the full extent of the PSA/PCA response 
in both strains of mutant mice, these aspects are discussed below.
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F ig 4.9 p i  lO yparticipates in the allergic response by o f  an autocrine loop. Initial 
IgE/antigen stimulated mast cell activation leads to the liberation o f autocrine 
GPCR agonists including adenosine which activate an autocrine loop, which 
provides a important burst o f  PI(3)K activity which overcomes SHIP down- 
regulation and promotes optimal mast cell degranulation.
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4.4.5.1 Disruption o f  a p i  lOy/phosphodiresterase complex inhibits 
cAMP metabolism.
The resistance of p i lOy null mice to IgE/antigen dependent passive systemic 
anaphylaxis may be a result of a defect in mast cell cAMP metabolism. Deletion of 
p i lOy may lead to a disruption of a protein complex which is important for 
recruiting the phosphodiesterase (PDE) enzyme to the adenosine receptor upon 
activation.
Cyclic adenosine monophosphate (cAMP) is a potent intracellular second messenger 
activated by a range of hormone receptors and GPCRs (Essayan 2001). Cyclic AMP 
is synthesized from adenosine triphosphate (ATP) by adenylate cyclase, and acts by 
binding to protein kinase A (PKA) causing dissociation of the PKA tetramer into its 
component monomers- two regulatory subunits with cAMP attached, and two active 
catalytic subunits. These events enable activation of PKA and phosphorylation of 
substrate proteins (Essayan 2001).
The activities of cyclic AMP are modulated by phosphodiesterases which hydrolyse 
the 3’-phosphodiester bond in cAMP, resulting in the formation of the corresponding 
inactive 5’-monophosphate (Essayan 2001). Disruption of PDE blocks hydrolysis of 
cAMP and causes accumulation of cyclic nucleotides, leading to increased PKA 
activity.
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p i lOy (together with other unknown molecular partners) is thought to have a 
scaffolding function and is important in recruiting the PDE-3B isoform to activated 
GPCR receptors, independently of its lipid-kinase activity (Patrucco, Notte et al.
2004). Loss of this negative control of PDE-3B upon loss-of-expression of pi lOy in 
the p i lOy KO mice is thought to lead to unrestrained PKA activity as a consequence 
of the failure to hydrolyse cAMP. This is thought to be the underlying cause of 
cardiac failure (induced by transverse aortic constriction) in mice lacking p i lOy 
expression (Patrucco, Notte et al. 2004). The importance of this kinase-independent 
scaffold function was documented in a comparison of p i lOy KO (lacking p i lOy 
expression) and so-called pi lOy KR mice (which express kinase-dead p i lOy). 
Unlike pi lOy KO (which have reduced PDE3B activity), p i lOy KR mice (with 
normal PDE3B activity) are protected from cardiac tissue damage caused by 
increased work load. It is possible that a similar effect on cAMP is also important in 
mast cells.
Inflammatory cells are extremely sensitive to alterations in cAMP levels. Elevation 
in cAMP levels through modulation of PDE activity by inhibitors can downregulate 
immune cell functions including the degranulation of mast cells (Essayan 2001). Of 
the 11 different classes of cAMP PDE isozymes identified, both cAMP PDE3 and 
PDE4 are expressed in mast cells (Essayan 2001).
Extracellular adenosine is thought to play a role in inflammatory airway diseases 
such as asthma and chronic obstructive pulmonary disease (COPD) (Polosa 2002).
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Adenosine is a nucleoside consisting of the purine base, adenine, in glycosidic 
linkage with the sugar, ribose. Extracellular adenosine is predominantly derived 
from the 5’-nucleotidase cleavage of adenosine 5’-monophosphate (AMP). Cellular 
production of adenosine is greatly enhanced under conditions of local hypoxia, as 
may occur in inflammation (Polosa 2002).
Mast cells are thought to play a major role in the bronchoconstrictor response to 
inhaled adenosine. In vitro adenosine can substantially enhance the release of 
histamine from mast cells, and is also liberated from activated mast cells following 
IgE/antigen crosslinking (Marquardt, Gruber et al. 1984; Marquardt and Walker 
1988). Adenosine activates a number of GPCR receptors expressed on the mast cell 
surface including A l, A2a, A2b and A3 (Forsythe and Ennis 1999; Laffargue, Calvez 
et al. 2002). Activation o f adenosine receptors can either stimulate (Al, A2B, A3) or 
inhibit (A2B) histamine release (Fig 4.8).
p i lOy is coupled to G ai -type GPCRs and signals through the A3 type adenosine 
receptor (Laffargue, Calvez et al. 2002). Activation of G«i type of GPCR receptors 
leads to recruitment of PDE and the breakdown of the cAMP messenger. It is 
therefore conceivable that if p i lOy is important for recruiting PDE (possibly 
PDE3B) in mast cells, disruption of the pi lOy/PDE complex will have a negative 
impact on mast cell activation by artificially increasing cAMP levels which would 
inhibit the release of mast cell derived pro-inflammatory mediators such as 
histamine, arachidonic acid and cytokines which may all contribute to the resistance
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of p i lOy KO mice to systemic anaphylaxis challenge (Fig 4.8) (Laffargue, Calvez et 
al. 2 0 0 2 ).
4.4.5.2 PI(2)K expression in the endothelium
Endothelial cells have been shown to express a significant quantity of p i 108 and 
p i lOy (Puri, Doggett et al. 2004; Puri, Doggett et al. 2005). Mast cells release a 
broad range of pro-inflammatory mediators (histamine, TNFa, VEGF, adenosine 
and others) many of which can enhance vasodilation thereby increasing vascular 
permeability (Metcalfe, Baram et al. 1997). Some of these mediators interact with 
receptors known to couple to class I PI3K isoforms, and for example include VEGF 
and adenosine which couple to class IA PI(3)Ks (such as p i 108) and class IB, 
respectively. Genetic or pharmacological inactivation of one or more of these 
isoforms within the endothelium may also have implications for the allergic 
response. Both the p i 108 and pi lOy studies have utilised experimental protocols 
which rely on vascular permeability as an endpoint and a measure of mast cell 
activation. It is possible that normal or partially reduced mast cell activation may 
have been masked by vascular endothelial defects. In other words mast cell-liberated 
products which are able to increase vascular permeability may interact with 
receptors which are dependent upon class I PI(3)K activity. Thus genetic 
inactivation or deletion of p i 108 and p i lOy respectively may have reduced the 
sensitivity of the vascular endothelium to these agonists and may have lead to mast 
cell independent effects which have confounded the interpretations relating to the 
sensitivity of p i io§D910A/D910A and p i lOy null mice to PCA and PSA responses.
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Fig 4.8 p llO y m a y  be a scaffold fo r  binding PDE. Adenosine receptors can either 
stimulate or inhibit mast cell degranulation, p i  lOy couples to God type o f adenosine 
receptor (A3) which stimulates histamine release by recruiting phosphodiesterase to 
break down cAMP which is the product o f inhibitory adenosine receptors (A2A,)■ I f  in 
mast cells p i  lOy is in a constitutive complex with PDE as is the case in cardiac 
tissue, then deletion o fp i lOy would impact PDE recruitment and artificially 
increase cAMP levels which would inhibit mast cell histamine release.
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5.0 General Discussion
Mast cells are central to IgE-dependent allergic inflammation and utilise PI(3)- 
kinase activity to support functions ranging from growth factor-induced proliferation 
and survival to IgE/antigen-activated exocytosis and cytokine production (Fukao, 
Terauchi et al. 2003). When we started our work, this evidence was mainly based on 
the observation that broad spectrum small molecule inhibitors of PI(3)K, such as 
wortmannin or LY294002, have a strong inhibitory effect on mast cell functions. 
While these inhibitors block all classes of PI(3)Ks, it is mainly the class IA subset of 
PI(3)Ks which was thought to drive a significant number of these PI(3)K-dependent 
responses in mast cells. Below, we give a general overview of our findings, for 
detailed discussions of the results, the Reader is referred to the indicated chapters.
To date, class IA-specific aspects of PI(3)K signalling have been primarily 
investigated using genetic deletion strategies which remove the stabilising elements 
of the heterodimeric p i 10/p85 PI(3)K complex, namely the ‘p85’ regulatory 
subunits. By removing p85 it was hoped that receptors and adaptor proteins would 
no longer be able to recruit / utilise the p i 10-kinase activity. This type of approaches 
provided the first genetic insight into the functions of class IA PI(3)K in mast cell 
biology. This work suggested that class IA PI(3)K is important for aspects of mast 
cell homeostasis directed through the Kit receptor but, surprisingly, appeared not to 
be required for mast cell activation through the FcsRI receptor (Lu-Kuo, Fruman et 
al. 2000; Fukao, Yamada et al. 2002; Fukao, Terauchi et al. 2003). The latter 
observations were surprising, given the strong inhibition of FcsRI receptor-driven
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responses by broad-spectrum PI(3)K inhibitors. Of course, it was possible that class 
IA PI(3)Ks, contrary to the expectations, were not involved in FcsRI receptor 
function.
The class LA PI(3)K is a family of 3 distinct p i 10 catalytic isoforms which couple to 
one of 5 regulatory adaptor proteins. Mast cells express all 3 class IA p i 10 catalytic 
subunits including the primarily leukocyte restricted p i 105 isozyme (Chantry, 
Vojtek et al. 1997; Vanhaesebroeck, Welham et al. 1997). Using a mouse model in 
which p i 105 (referred to as p ll0 5 D910A) has been inactivated we have assessed the 
role of this isoform in mast cell development (<chapter 3), activation (<chapter 4) and 
the in vivo allergic immune response (chapter 4).
Using cells derived from p i io5D910A/D910A mice we have determined that p i 105 
is the principal source of class LA PI(3)K activity available to mast cells {section 
3.2.2); genetic inactivation of p i 105 constitutes a ~90% reduction in total class IA 
lipid-kinase activity; it is therefore inevitable that disruption of such a large quantity 
of PI(3)K activity will most likely have an impact on class IA PI(3)K-dependent 
responses and will be a be a determinant in many of the p i 105-specific responses 
described in this study. There are also some indications that there may be some 
qualitative differences between receptor utilisation of PI(3)K isoforms, however it 
is not clear if these are (1) a product of the differential recruitment of PI(3)K 
isoforms (possibly via scaffold proteins which associate with different PI(3)Ks); (2) 
intrinsic differences in p i 10 isoforms (i.e. differences in pi 10 interactions with Ras,
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p i 10 protein kinase activity, including autophosphorylation) (3) the regulatory 
isoforms with which the p i 10s associate (p85a and p85(3 have additional N-terminal 
domains which extend their functions beyond recruiting/stabilising pi 1 0  and may 
recruit additional molecules which determine p i 1 0  activation status within specific 
receptor/adaptor complexes) (4) or a combination of the factors described above..
Im pact o f  p i  10 8  inactivation on growth factor-induced signalling and functional 
responses in m ast cells
In Chapter 3 we describe a series of phenotypes associated with p i 105 inactivation 
and growth factor-dependent responses. We have found the IL-3 and Kit receptors 
have a differential sensitivity to genetic or pharmacological p i 105 inactivation. 
Whereas IL-3 signalling and functional responses are almost-fully PI(3)K- 
dependent, they are only partially (up to -50% ) sensitive to p i 105 inhibition; the 
residual PI(3)K activity (together with pathways which are unaffected by PI(3)K 
inhibition, including MAPK) can maintain in vitro mast cell cultures. In contrast, 
PI(3)K-dependent Kit-receptor mediated responses (PKB phosphorylation, 
proliferation, adhesion and migration) are almost completely abrogated upon p i 105 
inactivation. In the discussion {section 3.3) we highlight several intrinsic differences 
between the IL-3 and Kit receptors which may determine this differential sensitivity, 
and which can be summarised as follows. In contrast to Kit, the IL-3 receptor has no 
direct binding site for class IA PI(3)Ks. Stimulation of the IL-3 receptor leads to the 
activation of Janus-family (JAK) PTKs which phosphorylate tyrosine residues on the 
IL-3 receptor p-chain which allows this receptor to recruit adaptor proteins including
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Gab2 and provides the receptor access to class IA PI(3)Ks. Gab2 is a Dos-family 
scaffold protein that contains YxxM sequences which can bind PI(3)K. As there is 
no known selectivity between p85/pll0  and YxxM sequences it is likely that all 
class IA subunits can couple to Gab2 (including p i 10a and p i 10(3) thus the residual 
PI(3)K activity downstream of IL-3 signalling may be a contribution of Gab2- 
associated p i 1 0 a  and pi 1 0 p activity.
The Kit receptor can also recruit Gab2/PI(3)K to augment the SCF-induced 
proliferation response. Indeed, in the absence of Gab2 (Gab2 null BMMC) SCF- 
stimulated PKB phosphorylation and mast cell proliferation are partially reduced. It 
is not clear as to why, under conditions in which p i 108 is inactive, the 
Kit/Gab2/PI(3)K does not drive at least a partial PI(3)K-dependent response. Several 
reasons to explain this may be put forward (1) it is possible that the Kit receptor 
cannot recruit sufficient Gab2/PI(3)K and therefore does not achieve a threshold to 
drive Kit-dependent PI(3)K signal(s)/response(s) (2) The Kit
receptor cannot recruit Gab2 as it may require an initial phase of p i 108-dependent 
PIP3 to do so (Gab2 is known to have a PIP3 interacting PH domain) (Rodrigues, 
Falasca et al. 2000). We have preliminary data to suggest that p i 108 may be 
associated with the Kit receptor under basal, unstimulated conditions; however it is 
not clear if pi 108 exclusively associates with the Kit receptor, or if  any association 
is «e>«-exclusive and that in the presence of all 3 isoforms p i 108 is specifically 
activated over p i 10a and pllOp (possibly by Kit receptor associated accessory 
molecules like Ras or Rac). (3) in the absence of a selective recruitment/association
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most of the constitutively associated Kit/PI(3)K will be pi 108 by virtue of a 
predominant expression level, this may impact on ( 1 ).
In section 3.2.4 we have described our observation that in the presence of the p i 105- 
selective inhibitor IC87114, IL-3-dependent (or IL-3 co-stimulated with SCF) mast 
cell proliferation and expansion are severely impaired. We conclude that as the yield 
of viable mast cell numbers is not significantly reduced under these conditions, the 
observed attenuation in mast cell expansion and proliferation may be as a 
consequence of a delay in cell cycle progression. Previously published work showed 
that expression of a dominant-negative p85a unable to bind p i 10 (Ap85a) in 
BMMC lead to a delay in progression through the G1 -phase of the cell cycle and a 
corresponding delay in mast cell expansion (Fox, Crew et al. 2005). We conclude 
that this may also be the case upon p i 108 inactivation and may also explain the 
substantially reduced number of mast cells (up to 50% less) derived from 
p i 105D910A/D910A bone marrow progenitors after a 4-week culture period.
Using histological analysis (section 3.2.7 and 3.3.2) we have determined the in vivo 
consequences of constitutive pi 108 inactivation on mast cell tissue distribution; 
p ll0 5 D910A/D910A mice have a tissue site-selective reduction in mast cell populations 
(primarily within the gastrointestinal tract and the peritoneum), p i 105-activity does 
not appear to have a global influence over all mast cell populations; these 
observations are in line published data from other mouse models in which PI(3)K 
activity has been directly or indirectly targeted, all these data including our own fit
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with the notion that class IA PI(3)K maintains the homeostasis of (a) specific 
subset(s) of mast cells (section 3.3.2).
The SCF/Kit receptor system is critical for the homeostasis of all mast cell 
populations as mutations which disrupt Kit receptor kinase activity severely reduce 
tissue all mast cell numbers. Our in vitro data indicate that p i 108 is critical for 
multiple Kit-dependent responses including proliferation, migration and adhesion, 
therefore there appears to be a discrepancy between our in vitro and in vivo data. 
Several possible explanations may be put forward to account for this apparent 
discrepancy (1) membrane-bound SCF (which we have not tested in our in vitro 
experiments) may not utilise the PI(3)K pathway and is sufficient to maintain most 
tissue mast cell populations. In a study which compared the properties of soluble and 
membrane-bound SCF. It was found that both of these growth factors can recruit p85 
to the activated Kit receptor and drive proliferation, membrane-bound SCF failed to 
activate PKB phosphorylation, which was in contrast with the strong PKB 
phosphorylation observed following stimulation of with soluble SCF. This study 
suggested that membrane-bound SCF stimulates less internalisation than soluble 
SCF which may be a requirement for association with downstream PI(3)K 
dependent signalling elements such as PKB (Trieselmann, Soboloff et al. 2003) (2) 
The defects in soluble SCF may be overcome in combination with other growth 
factors (3) Sites which appear particularly sensitive to reductions in PI(3)K activity 
may have (a) mast cell population(s) which has access to mainly (or only) soluble 
SCF and therefore is particularly sensitive to p i 108 inhibition.
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IgE/antigen-dependent m ast cell activation and the allergic immune response
In chapter 4 we describe our findings relating to mast cell activation and propose a 
model for p i 108 participation downstream of activated FcsRI-complexes {section 
4.4.5); this model is based on the evidence that p i io8D910A/D910A BMMCs which 
have a substantial reduction in IgE/antigen-dependent secretory granule exocytosis 
(~50% reduction) also have a substantially attenuated calcium response. In addition 
we highlight that IgE/antigen-dependent degranulation of WT mouse can be 
substantially attenuated by pretreatment with the p i 105-selective inhibitor IC87114. 
That acute pharmacological p i 108 inactivation mimics genetic inactivation of p i 108 
indicates that any potential developmental defects in p i 108D910A/D910A BMMCs do 
not play a significant role in the diminished IgE/antigen-triggered secretory granule 
exocytosis phenotype. Similar observations were made in human mast cells, 
indicating that our findings can be related directly to the human system.
In section 4.4.1.1 we propose two possible mechanisms by which p i 108 in activated 
FcsRI complexes can influence the calcium response: (1) by translocating/activating 
molecules into/within the LAT calcium ‘signalosome’ and thereby augmenting the 
activity of PLCy (known PI(3)K sensitive molecules involved in calcium 
mobilisation which may be effected by this PI(3)K activity include Tec family PTK 
(such as BTK) and GEFs) (2) direct / indirect (via BTK) activation of plasma 
membrane calcium channels to allow influx of calcium from the extracellular 
environment.
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However our model is in conflict with the broadly accepted idea that class IA PI(3)K 
is not significantly involved in the calcium-mobilising steps downstream of the 
activated FcsRI receptor (Blank and Rivera 2004). Recently it has been shown that 
BMMC degranulation can be dissected into two events (1) the calcium-independent 
microtubule-dependent translocation of granules to the plasma membrane and (2 ) 
calcium-dependent membrane fusion and exocytosis (Nishida, Yamasaki et al. 
2005). Class IA PI(3)K is thought to participate in the events described under (1) 
which it can influence through numerous PI(3)K-sensitive effector proteins via its 
interaction with an regulation of smalll GTPases via GEFs and GAPs, many of 
which are known to be involved in cytoskeletal reorganisation which can contribute 
to granule translocation events. However the critical contribution of class IA PI(3)K 
in the calcium-independent steps is thought by some to be through its activation of 
the calcium-z'fldependent 8  iso form of PKC (discussed below).
The activated FcsRI-receptor most likely accesses class LA PI(3)K indirectly via the 
scaffold protein Gab2. Indeed, genetic deletion of Gab2 or the upstream Src family 
PTK Fyn, essential for Gab2 phosphorylation, leads to a severe attenuation of 
FcsRI-dependent PI(3)K activity (90% and 80% in Fyn- and Gab2-null BMMCs, 
respectively, assessed using both PIP3 analysis and PKB phosphorylation), and 
BMMC secretory granule exocytosis (reduction of -80% and -65% in Fyn and 
Gab2 null BMMCs, respectively), in the absence of a significant defect in the 
calcium response. As a consequence of this reduction in PI(3)K activity, Fyn- and
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Gab2-deficient mice are resistant to IgE/antigen-dependent PSA (measured by 
histamine release) (Gu, Saito et al. 2001; Parravicini, Gadina et al. 2002).
The calcium-independent PKCS has been put forward as the critical downstream 
target of the Fyn/Gab2/PI(3)K pathway, essential for complimenting the calcium- 
dependent exocytosis process (downstream of Lyn/Syk/LAT). In Fyn-deficient 
BMMCs PKCS phosphorylation is substantially diminished and is thought to be the 
reason why these cells have a severe attenuation of degranulation (Parravicini, 
Gadina et al. 2002), upon this evidence and the lack of a significant reduction in the 
calcium response it was proposed that PKC dependent secretory granule exocytosis 
is essential for FceRI-dependent mast cell degranulation and that Gab2/PI(3)K is 
critical for PKC activation. The model that was proposed can be summarised as:
FcsRI => Fyn > Gab2 > PI(3)K > PDK-1 >PKC = Secretory granule exocytosis
A possible explanation which can accommodate both our own data and the model 
described above is if the pllOSD910A mutation disrupts both the Gab2 and LAT 
associated PI(3)K activity. Genetic deletion of Fyn or Gab2 removes the pool of 
class IA PI(3)K which activates PKC which is separate from the pool of PI(3)K 
which associates with LAT. Recently it has been shown that SLP-76(Shim, Moon et 
al. 2004) (which associates with LAT via the Gads adaptor protein) can directly bind 
the p85 subunit of PI(3)K. Deletion of SLP-76 attenuates calcium responses and the 
allergic response. Thus it is possible that the p ll0 8 D910A mutation disrupts both the
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Gab2 and the LAT associated class IA PI(3)K. In other words the p ll0 8 D910A 
mutation provides a more complete understanding of PI(3)K participation in FcsRI- 
dependent responses.
Important areas for future work will include analysis of the PI(3)K which associates 
with Gab2 and that which associates with LAT (Wilson, Pfeiffer et al. 2002). As the 
principal class IA PI(3)K pi 105 mutation would also be expected to impact the 
Gab2 pathway and PKC activation. It will therefore be of interest to see how PKC 
activity is affected upon pi 108 inactivation.
p i  10S inactivation can attenuate the in vivo allergic response 
In section 4.4.3 we discuss our findings relating to the role of p i 108 in the PC A and 
PSA response. We have found that genetic or acute pharmacological inactivation of 
p i 108 can substantially attenuate the PCA response to a level which is consistent 
with our in vitro mast cell activation data (~40-50% reduction). Furthermore at 
higher doses of IC87114 (where it may possibly start to affect the activity of p i lOy), 
the PCA response can be completely blocked. The role of p i 108 in the IgE/antigen- 
dependent PSA response is less clear. A confounding factor in these studies is the 
observation that p i io8D910A/D910A mice passively sensitised with IgE but not 
challenged with antigen already have a higher basal level of histamine. Several 
possible reasons which may explain these data have been put forward in section 
4.4.4.
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Interactions between p i  1 OS and p l l O y
In section 4.4.5 we discuss what has been referred to recently as a paradox between 
p i 108 and p i lOy (Wymann and Marone 2005). We put forward the suggestion that 
genetic deletion of pllOy may have affected a pllOy/PDE complex which is 
important for cAMP metabolism downstream of the autocrine loop. We also discuss 
the possibility that a defect in the endothelium could have confounded the 
interpretation of in vivo experiments in our own study and the p i lOy study, both of 
which have used vascular permeability as a measure o f mast cell activation.
Incom plete disruption o f  PI(3)-kinase activity and p 8 5  specific functions in p85- 
*K O  * m odels
Some of our observations are in conflict with data obtained from p85 KO studies. 
p85 KO strategies applied to date have removed only a fraction of the regulatory 
PI(3)K subunits available to mast cells, and it is not unlikely that the remaining 
regulatory subunits provide at least some of the PI(3)K activity downstream of 
activated receptors. This ‘reduced’ PI(3)K input may be insufficient in some cases to 
achieve the necessary thresholds to drive a functional response and lead to the 
reported phenotypes in these mice. However one data obtained from p85a-only null 
mice (in which p55a and p50a remain intact) provides data implying that some of 
the reported phenotypes may be a unique feature of disrupting the full-length p85a 
subunit. BMMCs derived from these mice express normal levels of p i 108 with some 
reduction in p i 10a expression (Fukao, Yamada et al. 2002). As we have shown
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p i 105 is the primary isoform downstream of the Kit receptor, thus it is not 
surprising that SCF stimulation of p85a null BMMCs leads to only a minor 
reduction in Akt/PKB phosphorylation (-30% reduction); under these conditions 
p i 105 coupled to the non-targeted p55a, p50a (which are both up-regulated in 
p85a-null mast cells)and p85(3 adaptor proteins can bind to the activated Kit 
receptor providing a signal which maintains most of the Kit/PI(3)K activity (-70% 
PKB signal). However, despite the fact that under these conditions PI(3)K activity 
appears only minimally reduced, the impact on Kit-driven proliferation appears to be 
severe, indicating that disruption of full length p85a in the absence of a significant 
defect in PI(3)K recruitment/activity is sufficient to impair Kit responses. In other 
words, full length p85a appears to have a rather specific role downstream of the Kit 
receptor. This may relate to the additional N-terminal domains present in p85a (and 
p85p) which extend their functions beyond p i 10 stabilisation. These include a BH 
domain which can interact with Rac and SH3 domains which can interact with 
proline-rich regions. Deletion of full length p85a appears to have a substantial 
impact on the JNK (60% reduction) pathway which is downstream of Rac activation 
(Fukao, Yamada et al. 2002). Thus it would appear that although the remaining 
regulatory adaptors can couple to Kit, in the absence of full length p85a they cannot 
compensate adequately for p85a-specific responses. We also find that JNK 
phosphorylation is partially disrupted in p i 105 KI BMCCs (approx 60%, data not 
shown). This would indicated that p85a-dependent responses are also to an extent 
PI(3 )-kinase dependent.
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Kit / p85a-specific coupling does not appear to be relevant to other PI(3)K- 
dependent receptors which unlike the Kit receptor (which can bind PI(3)K directly) 
recruit PI(3)K indirectly via scaffold proteins such as Gab2. p85a null BMMCs 
(both p85a-only KO and pan-p85a KO) have no defects in IL-3-induced 
proliferation or IgE/antigen-stimulated degranulation. Gab2 null BMMCs stimulated 
with IL-3 or IgE/antigen complexes have a substantial reduction in PKB 
phosphorylation (-75% and 80% respectively) (Xie, Ambudkar et al. 2002). 
Although it is not clear how the residual PI(3)K couples to these receptors in the 
absence of Gab2, it is clear that this scaffold is the primary access to class IA PI(3)K 
activity downstream of IL-3 and FcsRI receptors. Like most receptor and adaptor 
proteins which have YxxM sequences, Gab2 is not expected to have any preference 
for binding specific regulatory adaptor subunits (Vanhaesebroeck, Leevers et al. 
2001; Liu and Rohrschneider 2002). Thus it seems likely that in the absence of 
PIK3rl gene products, the remaining regulatory subunits coupled to p i 10 are 
recruited to Gab2 and provide necessary PI(3)K input to drive both IL-3 and FcsRI 
responses. Our data indicate that p i 108 is the principal class IA PI(3)K in mast cells 
therefore it would seem likely that most of the regulatory subunits are in complex 
with p i 108, thus most of the Gab2 recruited PI(3)K in p i io8D910A/D910A BMMCs 
will be ‘kinase-dead’ and thus our data to a large extent are compatible with findings 
from the Gab2 study (Gu, Saito et al. 2001).
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The im portance o f  careful gene-targeting
Mouse gene targeting is a powerful tool for dissecting signalling pathways.
However, like all molecular or pharmacological tools there is the potential for 
indirect or off-target effects. Genetic deletion strategies are prone to ‘artificial 
phenomena’ which may be consequence of losing important protein-protein 
interactions and in the case of molecules which are part of a large family, deletion of 
a specific member(s) may leave room for promiscuous signalling by the non­
targeted isoforms. Gene inactivation approaches are also prone to ‘knock-on’ effects 
such as the creation of a dominant-negative acting proteins or differentiation 
phenotypes as a result of ablation of early constitutive gene function, which can lead 
to compensatory mechanisms.
However it is possible to circumvent or at least reduce such scenarios by careful 
gene targeting. A dominant-negative is by definition is any mutation whose gene- 
product adversely affects the normal, WT gene-product within the same cell or 
organism. An example of this scenario in the case of class LA PI(3)Ks would be the 
creation of a regulatory subunit mutation such that adaptor proteins can no longer 
interact with p i 10 subunits (such as the Ap85a). This type of mutation would have a 
global effect on all class IA PI(3)K signalling. In contrast, the pi 108D910A mutation 
specifically interferes with the p i 105 molecule such that it is expressed as a 
constitutively inactive but structurally intact protein, p i 108D910A is able to fulfil any 
kinase-independent functions (including scaffolding) and to take its ‘normal’ 
molecular place within signalling complexes downstream of receptor activation.
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This strategy is not expected to have any effect on the functions of p i 10a or p i 10(3 
which remain active and free to take their ‘normal’ place within receptor complexes; 
therefore it is unlikely that the p i 106D910A creates a dominant-negative system.
The most relevant problem for any genetic approach involving the constitutive 
deletion or inactivation of a molecule(s) is the potential for developmental defects. 
We cannot exclude that developmental defects may contribute to the severity of 
some of the reported phenotypes; however we have also utilised a pharmacological 
p i 106 selective inhibitor and report that acute inactivation mimics our genetic data, 
strengthening our conclusions on the importance of p i 106 in mast cell biology. 
Overall the best strategy for dissecting signalling pathways is to use a combination 
of conditional ‘knock-out’ and ‘knock-in’ strategies combined with pharmacological 
and molecular approaches.
Sum m ary
In summary our data provide new insight into the role of p i 106 within a mast cell 
context and identifies important new functions for this PI(3)K in aspects of mast cell 
homeostasis, activation and the allergic immune response. Our data indicate that 
p i 106 inhibitors could be of clinical relevance in the treatment of mast cell 
pathologies including allergic disease. Future p i 106 inhibitors will most likely have 
a potent immune-suppressive effect by directly targeting the mast cell and by 
indirectly targeting immune cells which have a profound influence over mast cell 
biology, including the B-cell which has previously been shown to have a critical 
need for p i 106 activity.
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